1
|
Abouleisa RRE, Tang XL, Ou Q, Salama ABM, Woolard A, Hammouri D, Abdelhafez H, Cayton S, Abdulwali SK, Arai M, Sithu ID, Conklin DJ, Bolli R, Mohamed TMA. Gene therapy encoding cell cycle factors to treat chronic ischemic heart failure in rats. Cardiovasc Res 2024; 120:152-163. [PMID: 38175760 PMCID: PMC10936750 DOI: 10.1093/cvr/cvae002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 08/25/2023] [Accepted: 10/07/2023] [Indexed: 01/06/2024] Open
Abstract
AIMS Gene therapies to induce cardiomyocyte (CM) cell cycle re-entry have shown a potential to treat subacute ischaemic heart failure (IHF) but have not been tested in the more relevant setting of chronic IHF. Our group recently showed that polycistronic non-integrating lentivirus encoding Cdk1/CyclinB1 and Cdk4/CyclinD1 (TNNT2-4Fpolycistronic-NIL) is effective in inducing CM cell cycle re-entry and ameliorating subacute IHF models and preventing the subsequent IHF-induced congestions in the liver, kidneys, and lungs in rats and pigs. Here, we aim to test the long-term efficacy of TNNT2-4Fpolycistronic-NIL in a rat model of chronic IHF, a setting that differs pathophysiologically from subacute IHF and has greater clinical relevance. METHODS AND RESULTS Rats were subjected to a 2-h coronary occlusion followed by reperfusion; 4 weeks later, rats were injected intramyocardially with either TNNT2-4Fpolycistronic-NIL or LacZ-NIL. Four months post-viral injection, TNNT2-4Fpolycistronic-NIL-treated rats showed a significant reduction in scar size and a significant improvement in left ventricular (LV) systolic cardiac function but not in the LV dilatation associated with chronic IHF. A mitosis reporter system developed in our lab showed significant induction of CM mitotic activity in TNNT2-4Fpolycistronic-NIL-treated rats. CONCLUSION This study demonstrates, for the first time, that TNNT2-4Fpolycistronic-NIL gene therapy induces CM cell cycle re-entry in chronic IHF and improves LV function, and that this salubrious effect is sustained for at least 4 months. Given the high prevalence of chronic IHF, these results have significant clinical implications for developing a novel treatment for this deadly disease.
Collapse
Affiliation(s)
- Riham R E Abouleisa
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Xian-Liang Tang
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Qinghui Ou
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Abou-Bakr M Salama
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Cardiovascular Medicine, Faculty of Medicine, Zagazig University, 872 Shaibet an Nakareyah, Zagazig, Al-Sharqia Governorate 7120001, Egypt
| | - Amie Woolard
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Dana Hammouri
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Pharmacology and Toxicology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Hania Abdelhafez
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Bioengineering, Speed School of Engineering, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Sarah Cayton
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Sameeha K Abdulwali
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- College of Medicine, Alfaisal University, Interconnection of Al Takhassousi،Al Zahrawi Street, Riyadh 11533, Saudi Arabia
| | - Momo Arai
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- College of Medicine, Alfaisal University, Interconnection of Al Takhassousi،Al Zahrawi Street, Riyadh 11533, Saudi Arabia
| | - Israel D Sithu
- Department of Medicine, Center for Cardiometabolic Science, Envirome Institute, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Physiology, School of Medicine, University of Louisville, Louisville, 580 South Preston Street, KY 40202, USA
| | - Daniel J Conklin
- Department of Medicine, Center for Cardiometabolic Science, Envirome Institute, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Roberto Bolli
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
| | - Tamer M A Mohamed
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Pharmacology and Toxicology, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Bioengineering, Speed School of Engineering, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Medicine, Center for Cardiometabolic Science, Envirome Institute, University of Louisville, 580 South Preston Street, Louisville, KY 40202, USA
- Department of Biochemistry Faculty of Pharmacy, Zagazig University, 872 Shaibet an Nakareyah, Zagazig, Zagazig, Al-Sharqia Governorate 7120001, Egypt
- Institute of Cardiovascular Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK
- Surgery Department, Baylor College of Medicine, 6519 Fannin Street, Houston, TX, 77030, USA
| |
Collapse
|
2
|
Peng YJ, Li YH, Du C, Guo YS, Song JT, Jia CY, Zhang X, Liu MJ, Wang ZM, Liu B, Yan SL, Yang YX, Tang XL, Lin GX, Li XY, Zhang Y, Yuan JH, Xu SK, Chen CD, Lu JH, Zou X, Wan CS, Hu QH. [The cases of tracing the source of patients infected with Omicron variant of SARS-CoV-2 based on wastewater-based epidemiology in Shenzhen]. Zhonghua Yi Xue Za Zhi 2024; 104:302-307. [PMID: 38246776 DOI: 10.3760/cma.j.cn112137-20231016-00766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/23/2024]
Abstract
Wastewater-based epidemiology (WBE) is an emerging discipline, which has been applied to drug abuse tracking and infectious disease pathogen surveillance. During the COVID-19 epidemic, WBE has been applied to monitor the epidemic trend and SARS-CoV-2 variants etc. In order to detect hidden COVID-19 cases and prevent transmission in the community, wastewater surveillance system for monitoring SARS-CoV-2 RNA was developed in Shenzhen. The sewage sampling sites were set up in key places such as the port areas, urban villages and residential communities of Futian, Nanshan, Luohu and Yantian districts. From July 26 to November 30, 2022, a total of 369 sewage sampling sites were set up, covering 1.93 million people. Continuous sampling was carried out for 3 hours in the peak period of water use every day. Sewage virus enrichment and SARS-CoV-2 nucleic acid detection were carried out by polyethylene glycol precipitation method and RT-qPCR, and a positive water sample disposal process was molded. This article aims to introduce the case of source tracing of COVID-19 infected patients based on urban sewage in Shenzhen. The sewage monitoring of Honghu water treatment plant in Luohu District played an early warning role, and the source of infection was traced. In the disposal of positive water samples in Futian South Road, Futian District, the important experience of monitoring point layout was obtained. In the sewage monitoring of Nanshan village, Nanshan District, the existence of occult infection was revealed. Sharing the experience of tracing the source of COVID-19 patients to avoid the spread of COVID-19 in the community based on wastewater surveillance of SARS-CoV-2 RNA in Shenzhen, and summarizing the advantages and application prospects of sewage surveillance can provide new ideas for monitoring emerging or re-emerging pathogens that are known to exhibit gastrointestinal excretion in the future.
Collapse
Affiliation(s)
- Y J Peng
- Biosafety Research Center, School of Public Health, Southern Medical University, Guangzhou 510515, China
| | - Y H Li
- Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| | - C Du
- Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| | - Y S Guo
- Division of Public Health Emergency, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| | - J T Song
- Water Ecology and Environment Division, Shenzhen Ecology and Environment Bureau, Shenzhen 518040, China
| | - C Y Jia
- Water Ecology and Environment Division, Shenzhen Ecology and Environment Bureau, Shenzhen 518040, China
| | - X Zhang
- Water Ecology and Environment Division, Shenzhen Ecology and Environment Bureau, Shenzhen 518040, China
| | - M J Liu
- Futian District Water Affairs Bureau, Shenzhen 518035, China
| | - Z M Wang
- Futian District Water Affairs Bureau, Shenzhen 518035, China
| | - B Liu
- Division of Water Supply and Drainage Management, Futian District Water Affairs Bureau, Shenzhen 518035, China
| | - S L Yan
- Division of Drainage and Disaster Prevention, Nanshan District Water Affairs Bureau, Shenzhen 518052, China
| | - Y X Yang
- Division of Drainage and Disaster Prevention, Nanshan District Water Affairs Bureau, Shenzhen 518052, China
| | - X L Tang
- Luohu Management Branch of Ecology Environment Bureau of Shenzhen Municipality, Shenzhen 518001, China
| | - G X Lin
- Division of Environmental Management, Luohu Management Branch of Ecology Environment Bureau of Shenzhen Municipality, Shenzhen 518001, China
| | - X Y Li
- Futian District Center for Disease Control and Prevention, Shenzhen 518040, China
| | - Y Zhang
- Department of Microbiological Laboratory, Futian District Center for Disease Control and Prevention, Shenzhen 518040, China
| | - J H Yuan
- Nanshan District Center for Disease Control and Prevention, Shenzhen 518054, China
| | - S K Xu
- Department of Infectious Disease Control and Prevention, Nanshan District Center for Disease Control and Prevention, Shenzhen 518054, China
| | - C D Chen
- Luohu District Center for Disease Control and Prevention, Shenzhen 518020, China
| | - J H Lu
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| | - X Zou
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| | - C S Wan
- Biosafety Research Center, School of Public Health, Southern Medical University, Guangzhou 510515, China BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China
| | - Q H Hu
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
| |
Collapse
|
3
|
Tang XL, Bolli R. Repeated Intravenous Administration of Mesenchymal Stromal Cells Produces Cumulative Beneficial Effects in Chronic Ischemic Cardiomyopathy. Tex Heart Inst J 2023; 50:e238244. [PMID: 37840224 PMCID: PMC10658144 DOI: 10.14503/thij-23-8244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2023]
Affiliation(s)
- Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky
| | - Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky
| |
Collapse
|
4
|
Tang XL, Nasr M, Zheng S, Zoubul T, Stephan JK, Uchida S, Singhal R, Khan A, Gumpert A, Bolli R, Wysoczynski M. Bone Marrow and Wharton's Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy. Stem Cell Rev Rep 2023; 19:2429-2446. [PMID: 37500831 PMCID: PMC10579184 DOI: 10.1007/s12015-023-10590-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2023] [Indexed: 07/29/2023]
Abstract
BACKGROUND Although cell therapy provides benefits for outcomes of heart failure, the most optimal cell type to be used clinically remains unknown. Most of the cell products used for therapy in humans require in vitro expansion to obtain a suitable number of cells for treatment; however, the clinical background of the donor and limited starting material may result in the impaired proliferative and reparative capacity of the cells expanded in vitro. Wharton's jelly mesenchymal cells (WJ MSCs) provide a multitude of advantages over adult tissue-derived cell products for therapy. These include large starting tissue material, superior proliferative capacity, and disease-free donors. Thus, WJ MSC if effective would be the most optimal cell source for clinical use. OBJECTIVES This study evaluated the therapeutic efficacy of Wharton's jelly (WJ) and bone marrow (BM) mesenchymal stromal cells (MSCs) in chronic ischemic cardiomyopathy in rats. METHODS Human WJ MSCs and BM MSCs were expanded in vitro, characterized, and evaluated for therapeutic efficacy in a immunodeficient rat model of ischemic cardiomyopathy. Cardiac function was evaluated with hemodynamics and echocardiography. The extent of cardiac fibrosis, hypertrophy, and inflammation was assessed with histological analysis. RESULTS In vitro analysis revealed that WJ MSCs and BM MSCs are morphologically and immunophenotypically indistinguishable. Nevertheless, the functional analysis showed that WJ MSCs have a superior proliferative capacity, less senescent phenotype, and distinct transcriptomic profile compared to BM MSC. WJ MSCs and BM MSC injected in rat hearts chronically after MI produced a small, but not significant improvement in heart structure and function. Histological analysis showed no difference in the scar size, collagen content, cardiomyocyte cross-sectional area, and immune cell count. CONCLUSIONS Human WJ and BM MSC have a small but not significant effect on cardiac structure and function when injected intramyocardially in immunodeficient rats chronically after MI.
Collapse
Affiliation(s)
- Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, KY, USA
| | - Marjan Nasr
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA
| | - Shirong Zheng
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA
| | - Taylor Zoubul
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA
| | - Jonah K Stephan
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA
| | - Shizuka Uchida
- Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
| | - Richa Singhal
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA
| | - Aisha Khan
- Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Anna Gumpert
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, KY, USA
| | - Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, KY, USA
| | - Marcin Wysoczynski
- Center for Cardiometabolic Science, University of Louisville School of Medicine, 580 South Preston St. - Rm 204B, Louisville, KY, 40202, USA.
| |
Collapse
|
5
|
Salama ABM, Abouleisa RRE, Ou Q, Tang XL, Alhariry N, Hassan S, Gebreil A, Dastagir M, Abdulwali F, Bolli R, Mohamed TMA. Transient gene therapy using cell cycle factors reverses renin-angiotensin-aldosterone system activation in heart failure rat model. Mol Cell Biochem 2023; 478:1245-1250. [PMID: 36282351 PMCID: PMC10126184 DOI: 10.1007/s11010-022-04590-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 10/13/2022] [Indexed: 10/31/2022]
Abstract
The loss of cardiomyocytes after myocardial infarction (MI) leads to heart failure. Recently, we demonstrated that transient overexpression of 4 cell cycle factors (4F), using a polycistronic non-integrating lentivirus (TNNT2-4F-NIL) resulted in significant improvement in cardiac function in a rat model of MI. Yet, it is crucial to demonstrate the reversal of the heart failure-related pathophysiological manifestations, such as renin-angiotensin-aldosterone system activation (RAAS). To assess that, Fisher 344 rats were randomized to receive TNNT2-4F-NIL or control virus seven days after coronary occlusion for 2 h followed by reperfusion. 4 months after treatment, N-terminal pro-brain natriuretic peptide, plasma renin activity, and aldosterone levels returned to the normal levels in rats treated with TNNT2-4F-NIL but not in vehicle-treated rats. Furthermore, the TNNT2-4F-NIL-treated group showed significantly less liver and kidney congestion than vehicle-treated rats. Thus, we conclude that in rat models of MI, TNNT2-4F-NIL reverses RAAS activation and subsequent systemic congestion.
Collapse
Affiliation(s)
- Abou Bakr M Salama
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
- Department of Cardiac Surgery, University of Verona, Verona, Italy
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Riham R E Abouleisa
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Qinghui Ou
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Xian-Liang Tang
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Nashwah Alhariry
- Department of Pathology, Faculty of Medicine, Suez University, Ismailia, Egypt
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Sarah Hassan
- Department of Electron Microscopy, Theodor Bilharz Research Institute, Imbaba Giza, Egypt
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Ahmad Gebreil
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Muzammil Dastagir
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Fareeha Abdulwali
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Roberto Bolli
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
- Department of Bioengineering, University of Louisville, Louisville, KY, USA
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Tamer M A Mohamed
- Department of Medicine, Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA.
- Department of Electron Microscopy, Theodor Bilharz Research Institute, Imbaba Giza, Egypt.
- Department of Bioengineering, University of Louisville, Louisville, KY, USA.
- Diabetes and Obesity Center, Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY, USA.
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA.
- Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
- Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street, Louisville, KY, 40202, USA.
| |
Collapse
|
6
|
Liu JH, Liu JR, Tang XL, Yang HM, Liu H, Xu H, Li HM, Zhao SY. [Predictive factors for sequelae of bronchitis obliterans in refractory Mycoplasma pneumoniae pneumonia]. Zhonghua Er Ke Za Zhi 2023; 61:317-321. [PMID: 37011976 DOI: 10.3760/cma.j.cn112140-20220902-00775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
Objective: To investigate the predictive factors for bronchitis obliterans in refractory Mycoplasma pneumoniae pneumonia (RMPP). Methods: A restrospective case summary was conducted 230 patients with RMPP admitted to the Department of No.2 Respiratory Medicine of Beijing Children's Hospital, Capital Medical University from January 2013 to June 2017 were recruited. Clinical data, laboratory results, imaging results and follow-up data were collected. Based on bronchoscopy and imaging findings 1 year after discharge, all patients were divided into two groups: one group had sequelae of bronchitis obliterans (sequelae group) and the other group had not bronchitis obliterans (control group), independent sample t-test and nonparametric test were used to compare the differences in clinical features between the two groups. Receiver operating characteristic (ROC) curve to explore the predictive value of Bronchitis Obliterans in RMPP. Results: Among 230 RMPP children, there were 115 males and 115 females, 95 cases had sequelae group, the age of disease onset was (7.1±2.8) years;135 cases had control group, the age of disease onset was (6.8±2.7) years. The duration of fever, C-reative protein (CRP) and lactate dehydrogenase (LDH) levels, the proportion of ≥2/3 lobe consolidation, pleural effusion and the proportion of airway mucus plug and mucosal necrosis were longer or higher in the sequelae group than those in the control group ((17±9) vs. (12±3) d, (193±59) vs. (98±42) mg/L,730 (660, 814) vs. 486 (452, 522) U/L, 89 cases (93.7%) vs. 73 cases (54.1%), 73 cases (76.8%) vs.59 cases (43.7%), 81 cases (85.3%) vs. 20 cases (14.8%), 67 cases (70.5%) vs. 9 cases (6.7%), t=5.76, 13.35, Z=-6.41, χ2=14.64, 25.04, 22.85, 102.78, all P<0.001). Multivariate Logistic regression analysis showed that the duration of fever ≥10 days (OR=1.200, 95%CI 1.014-1.419), CRP levels increased (OR=1.033, 95%CI 1.022-1.044) and LDH levels increased (OR=1.001, 95%CI 1.000-1.003) were the risk factors for sequelae of bronchitis obliterans in RMPP. ROC curve analysis showed that CRP 137 mg/L had a sensitivity of 82.1% and a specificity of 80.1%; LDH 471 U/L had a sensitivity of 62.7% and a specificity of 60.3% for predicting the development of bronchitis obliterans. Conclusions: The long duration of fever (≥10 d), CRP increase (≥137 mg/L) may be used to predict the occurrence of sequelae of bronchitis obliterans in RMPP. It is helpful for early recognition of risk children.
Collapse
Affiliation(s)
- J H Liu
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - J R Liu
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - X L Tang
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - H M Yang
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - H Liu
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - H Xu
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - H M Li
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| | - S Y Zhao
- Department of No.2 Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Disease, National Center for Children's Health, Beijing 100045, China
| |
Collapse
|
7
|
Bolli R, Tang XL. New insights into cardioprotection, gained by adopting the CAESAR standards of rigor. Basic Res Cardiol 2022; 117:57. [PMID: 36367590 DOI: 10.1007/s00395-022-00964-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 10/31/2022] [Accepted: 10/31/2022] [Indexed: 11/13/2022]
Affiliation(s)
- Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY, 40292, USA.
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY, 40292, USA
| |
Collapse
|
8
|
Yu JJ, Lei S, Li FL, Chen SS, Tang XL. [Effects of Porphyromonas gingivalis injected through tail vein on the expressions of biomarkers in neural stem cells and neurons of wild-type rats hippocampus]. Zhonghua Kou Qiang Yi Xue Za Zhi 2022; 57:375-383. [PMID: 35359079 DOI: 10.3760/cma.j.cn112144-20220214-00059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objectives: To study the effects of Porphyromonas gingivalis (Pg) injected through tail vein on the molecular expression levels of biomarkers of neural stem cells (NSC) and neurons in the hippocampus of wild-type adult rats, and the effects on hippocampal neurogenesis. Methods: Eighteen male Sprague-Dawley (SD) rats were randomly divided into 3 groups based on the table of random numbers (n=6 in each group). In low-intensity group and high-intensity group, rats were injected intravenously through tail vein with 200 μl Pg ATCC33277 [1.0×103 and 1.0×108 colony forming unit (CFU), respectively] 3 times per week for 8 weeks. In the sham group, 200 μl of phosphate buffer saline (PBS) was given instead. Behavioral tests: the navigation and the exploration tests using Morris water maze (MWM) were applied to evaluate learning and memory ability of rats. Immunohistochemistry was performed to detect cells positively expressing nestin, doublecortin (DCX) and neuronal nuclei (NeuN) in the subgranular zone (SGZ) of rats in each group. Western blotting was used to evaluate the expression levels of nestin, DCX and NeuN in rat hippocampus. Results: Learning and memory abilities: on day 5 of navigation test, the lagency time was 22.83 (16.00, 38.34) s in the high-intensity group, significantly longer than the sham group [5.59 (5.41, 6.17) s] (t=-11.17, P<0.001). There were no significant differences between the low-intensity group [9.85 (8.75, 21.01) s] and the sham group (t=-6.83, P=0.080). Results in the exploration test showed that, in the high-intensity group, the number of fime crossing over the previous platform area within 60 s was 1.50 (1.00, 2.00), significantly less than the sham group [4.00 (2.75, 4.00)] (t=9.75, P=0.003); no significant differences between the low-intensity group [2.50 (2.00, 3.00)] and the sham one (t=4.50, P=0.382). Immunohistochemistry showed that the nestin+ cell density in the low-intensity group [(35.36±4.32) cell/mm2] and high-intensity group [(26.51±5.89) cell/mm2] were significantly lower than the sham group [(59.58±14.15) cell/mm2] (t=24.21, P=0.018; t=33.07, P=0.005); as for the mean absorbance of DCX+ cells, the low-intensity group (0.007±0.002) and the high-intensity group (0.006±0.002) were significantly lower than the sham group (0.011±0.001) (t=0.004, P=0.018; t=0.006, P=0.005); compared with the sham group [(1.13±0.14)×103 cell/mm2], the density of NeuN+ neurons in the high-intensity group [(0.75±0.08)×103 cell/mm2] was significantly reduced (t=0.38, P=0.017), and was not significantly changed in the low-intensity group [(0.88±0.19)×103 cell/mm2] (t=0.25, P=0.075). Western blotting results showed that, compared with the sham group, the expression levels of nestin, DCX, and NeuN were significantly reduced in the high-intensity group (t=0.74, P<0.001; t=0.18, P=0.014; t=0.35, P=0.008), but were not statistically changed in the low-intensity group (t=0.18, P=0.108; t=0.08, P=0.172; t=0.19, P=0.077). Conclusions: Pg injected through tail vein may reduce learning and memory abilities of wild-type rats, and may reduce the number of nestin, DCX, and NeuN-positive cells, and the protein expression levels of the above molecules in the hippocampus.
Collapse
Affiliation(s)
- J J Yu
- Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang 110002, China
| | - S Lei
- Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang 110002, China
| | - F L Li
- Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang 110002, China
| | - S S Chen
- Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang 110002, China
| | - X L Tang
- Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang 110002, China
| |
Collapse
|
9
|
Tang XL, Wysoczynski M, Gumpert AM, Li Y, Wu WJ, Li H, Stowers H, Bolli R. Effect of intravenous cell therapy in rats with old myocardial infarction. Mol Cell Biochem 2022; 477:431-444. [PMID: 34783963 PMCID: PMC8896398 DOI: 10.1007/s11010-021-04283-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 10/21/2021] [Indexed: 10/19/2022]
Abstract
Mounting evidence shows that cell therapy provides therapeutic benefits in experimental and clinical settings of chronic heart failure. However, direct cardiac delivery of cells via transendocardial injection is logistically complex, expensive, entails risks, and is not amenable to multiple dosing. Intravenous administration would be a more convenient and clinically applicable route for cell therapy. Thus, we determined whether intravenous infusion of three widely used cell types improves left ventricular (LV) function and structure and compared their efficacy. Rats with a 30-day-old myocardial infarction (MI) received intravenous infusion of vehicle (PBS) or 1 of 3 types of cells: bone marrow mesenchymal stromal cells (MSCs), cardiac mesenchymal cells (CMCs), and c-kit-positive cardiac cells (CPCs), at a dose of 12 × 106 cells. Rats were followed for 35 days after treatment to determine LV functional status by serial echocardiography and hemodynamic studies. Blood samples were collected for Hemavet analysis to determine inflammatory cell profile. LV ejection fraction (EF) dropped ≥ 20 points in all hearts at 30 days after MI and deteriorated further at 35-day follow-up in the vehicle-treated group. In contrast, deterioration of EF was halted in rats that received MSCs and attenuated in those that received CMCs or CPCs. None of the 3 types of cells significantly altered scar size, myocardial content of collagen or CD45-positive cells, or Hemavet profile. This study demonstrates that a single intravenous administration of 3 types of cells in rats with chronic ischemic cardiomyopathy is effective in attenuating the progressive deterioration in LV function. The extent of LV functional improvement was greatest with CPCs, intermediate with CMCs, and least with MSCs.
Collapse
Affiliation(s)
- Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Marcin Wysoczynski
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Anna M Gumpert
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Yan Li
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Wen-Jian Wu
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Hong Li
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Heather Stowers
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | - Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA.
| |
Collapse
|
10
|
Abouleisa RR, Salama ABM, Ou Q, Tang XL, Solanki M, Guo Y, Nong Y, McNally L, Lorkiewicz PK, Kassem KM, Ahern BM, Choudhary K, Thomas R, Huang Y, Juhardeen HR, Siddique A, Ifthikar Z, Hammad SK, El-Baz AS, Ivey KN, Conklin DJ, Satin J, Hill BG, Srivastava D, Bolli R, Mohamed TM. Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure. Circulation 2022; 145:1339-1355. [PMID: 35061545 PMCID: PMC9038650 DOI: 10.1161/circulationaha.121.057641] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
The regenerative capacity of the heart after myocardial infarction (MI) is limited. Our previous study showed that ectopic introduction of Cdk1/CyclinB1 and Cdk4/CyclinD1 complexes (4F) promotes cardiomyocyte proliferation in 15-20% of infected cardiomyocytes
in vitro
and
in vivo
and improves cardiac function after MI in mice.
Methods:
Here, using temporal single-cell RNAseq we aimed to identify the necessary reprogramming stages during the forced cardiomyocyte proliferation with 4F on a single cell basis. Also, using rat and pig models of ischemic heart failure, we aimed to start the first preclinical testing to introduce 4F gene therapy as a candidate for the treatment of ischemia-induced heart failure.
Results:
Temporal bulk and single-cell RNAseq and further biochemical validations of mature hiPS-CMs treated with either LacZ or 4F adenoviruses revealed full cell cycle reprogramming in 15% of the cardiomyocyte population at 48 h post-infection with 4F, which was mainly associated with sarcomere disassembly and metabolic reprogramming (n=3/timepoint/group). Transient overexpression of 4F, specifically in cardiomyocytes, was achieved using a polycistronic non-integrating lentivirus (NIL) encoding the 4F; each is driven by a TNNT2 promoter (TNNT2-4Fpolycistronic-NIL). TNNT2-4Fpolycistronic-NIL or control virus was injected intramyocardially one week after MI in rats (n=10/group) or pigs (n=6-7/group). Four weeks post-injection, TNNT2-4Fpolycistronic-NIL treated animals showed significant improvement in left ventricular ejection fraction and scar size compared with the control virus treated animals. At four months after treatment, rats that received TNNT2-4Fpolycistronic-NIL still showed a sustained improvement in cardiac function and no obvious development of cardiac arrhythmias or systemic tumorigenesis (n=10/group).
Conclusions:
This study provides mechanistic insights into the process of forced cardiomyocyte proliferation and advances the clinical feasibility of this approach by minimizing the oncogenic potential of the cell cycle factors thanks to the use of a novel transient and cardiomyocyte-specific viral construct.
Collapse
Affiliation(s)
- Riham R.E. Abouleisa
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Abou Bakr M. Salama
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY; Faculty of Medicine, Zagazig University, Egypt
| | - Qinghui Ou
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Xian-Liang Tang
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Mitesh Solanki
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Yiru Guo
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Yibing Nong
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Lindsey McNally
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY
| | - Pawel K. Lorkiewicz
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY
| | - Kamal M. Kassem
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | | | | | | | - Yu Huang
- Gladstone Institute, San Francisco, CA
| | | | - Aisha Siddique
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Zainab Ifthikar
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Sally K. Hammad
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY; Department of Biochemistry Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Ayman S. El-Baz
- Department of Bioengineering, Speed School of Engineering, University of Louisville, KY
| | | | - Daniel J. Conklin
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY
| | | | - Bradford G. Hill
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY
| | | | - Roberto Bolli
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY
| | - Tamer M.A. Mohamed
- From the Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY; Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY; Department of Bioengineering, Speed School of Engineering, University of Louisville, KY; Department of Pharmacology and Toxicology, University of Louisville, KY; Institute of Cardiovascular Sciences, University of Manchester, U.K
| |
Collapse
|
11
|
Affiliation(s)
- Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| |
Collapse
|
12
|
Liu JJ, Fu SB, Jiang J, Tang XL. Association between outdoor particulate air pollution and the risk of osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2021; 32:1911-1919. [PMID: 33954814 DOI: 10.1007/s00198-021-05961-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 04/13/2021] [Indexed: 11/25/2022]
Abstract
Air pollution is a major threat to global health, which is associated with several adverse health outcomes and increased mortality. Few studies have investigated the association between air pollution and osteoporosis, and their findings were inconclusive. Our objective is to determine whether exposure to outdoor air pollution is causally associated with risk of osteoporosis. A systematic literature search of PubMed, Web of Science, Embase, and Cochrane Library for publications up to December 2020 was conducted for studies reporting the association between air pollution and osteoporosis. Meta-analysis was performed to estimate the pooled effect size of air pollution on osteoporosis using the relative risk (RR) and 95% confidence intervals (95% CI). Quality assessment was conducted, and all statistical analyses were performed by RevMan 5.3 software. Our search identified 9 eligible studies involving 9,371,212 patients. Meta-analysis revealed that there was an increased risk of osteoporosis (total body BMD and hip fracture) as a result of exposure to air pollution including PM2.5 and NO2. However, no significant excess risk of osteoporosis was found regardless of PM10, NO, and O3. In spite of a few number of epidemiological studies selected in the present literature review, this study indicated that the increased exposure to air pollutants was positively associated with high risk of osteoporosis. Further cohort studies with large sample sizes are needed to investigate different constituents and the duration of exposure of air pollutants.
Collapse
Affiliation(s)
- J J Liu
- Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, China
| | - S B Fu
- Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, China
| | - J Jiang
- The First Clinical Medical College of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, China
| | - X L Tang
- Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, China.
| |
Collapse
|
13
|
Liu H, Li HM, Liu JR, Yang HM, Xu H, Tang XL, Shen YL, Zhao YH, Zhao SY. [Clinical features and early diagnostic clues of chronic granulomatous disease]. Zhonghua Er Ke Za Zhi 2021; 59:777-781. [PMID: 34645219 DOI: 10.3760/cma.j.cn112140-20210426-00348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the early clinical clues for diagnosis of chronic granulomatous disease (CGD). Methods: One hundred and thirty-nine children with CGD seen in Beijing Children's Hospital from January 2007 to October 2020 were included in this study. The clinical features including age of onset, first presentations, reason for being hospitalized, etiology, imaging features, clues for early diagnosis of all patients were evaluated retrospectively. According to the time of diagnosis, the patients were divided into two groups, cases diagnosed before 2015 and after 2015 and 2015. The time of diagnosis, the length of stay and the hospital charges were compared between the two groups. T test and χ2 test were used for statistical analyses. Results: One hundred and nineteen of the cases were males and 20 were females. The age of onset was 4 months (8 d to 14 years), and 103 cases (74.1%) had onset before 1 year of age. The age at diagnosis was 1.8 years (21 d to 14.7 years), and the time of diagnosis delay was 1 year (7 d to 13.7 years). One hundred and thirty-five cases (97.1%) had pulmonary infection as the main reason for hospitalization, of whom 76 cases (56.3%) had positive pulmonary etiology. One hundred and thirty-six patients (97.8%) were referred cases, of whom 5 were suspected of CGD before referral, and the misdiagnosis rate was as high as 96.3% (131/136). Eight early clues for diagnosis were found, the frequency from high to low, large bacillus Callmette-Guer scar in 99 cases (70.5%), left axillary lymphadenopathy or calcification in 73 cases (52.5%), skin or other lymph node infections in 58 cases (41.7%), skin scars in 50 cases (36.0%), multiple lung nodules in 42 cases (30.2%), perianal abscess in 35 cases (25.2%), pulmonary Aspergillus infection in 26 cases (18.7%) and pulmonary Burkholderia infection in 15 cases (10.8%). A total of 120 cases of CGD were diagnosed by respiratory burst test during hospitalization, including 55 cases diagnosed before 2015 and 65 cases diagnosed after 2015. After using these 8 early diagnosis clues, the cases diagnosed after 2015 had shorter time of diagnosis and the length of stay and lower hospitalization charge than cases diagnosed before 2014, and the difference was statistically significant ((25±7) vs. (10±5) d, (29±7) vs. (18±6) d, (3.7×104±1.2×104) vs. (3.2×104±1.2×104) Yuan, t=13.763, 9.262, 2.381, all P<0.05). Conclusions: Patients with CGD are younger at onset and the diagnosis is delayed. Pulmonary infections are the most common. Large BCG scar, left axillary lymphadenopathy or calcification, skin or other lymph node infections, skin scars, multiple lung nodules, perianal abscesses, pulmonary Aspergillus infection and Burkholderia infection can help early diagnosis of CGD.
Collapse
Affiliation(s)
- H Liu
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - H M Li
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - J R Liu
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - H M Yang
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - H Xu
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - X L Tang
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - Y L Shen
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - Y H Zhao
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - S Y Zhao
- Department No.2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| |
Collapse
|
14
|
Ding XW, Zheng ZC, Zhao Q, Zhai G, Liang H, Wu X, Zhu ZG, Wang HJ, He QS, He XL, Du YA, Chen LC, Hua YW, Huang CM, Xue YW, Zhou Y, Zhou YB, Wu D, Fang XD, Dai YG, Zhang HW, Cao JQ, Li LP, Chai J, Tao KX, Li GL, Jie ZG, Ge J, Xu ZF, Zhang WB, Li QY, Zhao P, Ma ZQ, Yan ZL, Zheng GL, Yan Y, Tang XL, Zhou X. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data]. Zhonghua Wei Chang Wai Ke Za Zhi 2021; 24:403-412. [PMID: 34000769 DOI: 10.3760/cma.j.cn.441530-20200111-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the effect of perioperative chemotherapy on the prognosis of gastric cancer patients under real-world condition. Methods: A retrospective cohort study was carried out. Real world data of gastric cancer patients receiving perioperative chemotherapy and surgery + adjuvant chemotherapy in 33 domestic hospitals from January 1, 2014 to January 31, 2016 were collected. Inclusion criteria: (1) gastric adenocarcinoma was confirmed by histopathology, and clinical stage was cT2-4aN0-3M0 (AJCC 8th edition); (2) D2 radical gastric cancer surgery was performed; (3) at least one cycle of neoadjuvant chemotherapy (NAC) was completed; (4) at least 4 cycles of adjuvant chemotherapy (AC) [SOX (S-1+oxaliplatin) or CapeOX (capecitabine + oxaliplatin)] were completed. Exclusion criteria: (1) complicated with other malignant tumors; (2) radiotherapy received; (3) patients with incomplete data. The enrolled patients who received neoadjuvant chemotherapy and adjuvant chemotherapy were included in the perioperative chemotherapy group, and those who received only postoperative adjuvant chemotherapy were included in the surgery + adjuvant chemotherapy group. Propensity score matching (PSM) method was used to control selection bias. The primary outcome were overall survival (OS) and progression-free survival (PFS) after PSM. OS was defined as the time from the first neoadjuvant chemotherapy (operation + adjuvant chemotherapy group: from the date of operation) to the last effective follow-up or death. PFS was defined as the time from the first neoadjuvant chemotherapy (operation + adjuvant chemotherapy group: from the date of operation) to the first imaging diagnosis of tumor progression or death. The Kaplan-Meier method was used to estimate the survival rate, and the Cox proportional hazards model was used to evaluate the independent effect of perioperative chemo therapy on OS and PFS. Results: 2 045 cases were included, including 1 293 cases in the surgery+adjuvant chemotherapy group and 752 cases in the perioperative chemotherapy group. After PSM, 492 pairs were included in the analysis. There were no statistically significant differences in gender, age, body mass index, tumor stage before treatment, and tumor location between the two groups (all P>0.05). Compared with the surgery + adjuvant chemotherapy group, patients in the perioperative chemotherapy group had higher proportion of total gastrectomy (χ(2)=40.526, P<0.001), smaller maximum tumor diameter (t=3.969, P<0.001), less number of metastatic lymph nodes (t=1.343, P<0.001), lower ratio of vessel invasion (χ(2)=11.897, P=0.001) and nerve invasion (χ(2)=12.338, P<0.001). In the perioperative chemotherapy group and surgery + adjuvant chemotherapy group, 24 cases (4.9%) and 17 cases (3.4%) developed postoperative complications, respectively, and no significant difference was found between two groups (χ(2)=0.815, P=0.367). The median OS of the perioperative chemotherapy group was longer than that of the surgery + adjuvant chemotherapy group (65 months vs. 45 months, HR: 0.74, 95% CI: 0.62-0.89, P=0.001); the median PFS of the perioperative chemotherapy group was also longer than that of the surgery+adjuvant chemotherapy group (56 months vs. 36 months, HR=0.72, 95% CI:0.61-0.85, P<0.001). The forest plot results of subgroup analysis showed that both men and women could benefit from perioperative chemotherapy (all P<0.05); patients over 45 years of age (P<0.05) and with normal body mass (P<0.01) could benefit significantly; patients with cTNM stage II and III presented a trend of benefit or could benefit significantly (P<0.05); patients with signet ring cell carcinoma benefited little (P>0.05); tumors in the gastric body and gastric antrum benefited more significantly (P<0.05). Conclusion: Perioperative chemotherapy can improve the prognosis of gastric cancer patients.
Collapse
Affiliation(s)
- X W Ding
- Department of Gastric surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer Prevention and Therapy, Tianjin 300060, China
| | - Z C Zheng
- Department of Gastric Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, China
| | - Q Zhao
- The Third Department of Surgery, The Fourth Hospital, Hebei Medical University, Shijiazhuang 050011, China
| | - G Zhai
- Department of General Surgery, Shanxi Provincial Tumor Hospital, Taiyuan 030013, China
| | - H Liang
- Department of Gastric surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer Prevention and Therapy, Tianjin 300060, China
| | - X Wu
- Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| | - Z G Zhu
- Department of Surgery, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai 200025, China
| | - H J Wang
- Department of Gastrointestinal Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi 830011, China
| | - Q S He
- Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China
| | - X L He
- Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an 710038, China
| | - Y A Du
- Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China
| | - L C Chen
- Department of Gastrointestinal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China
| | - Y W Hua
- Department of General Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - C M Huang
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350004, China
| | - Y W Xue
- Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China
| | - Y Zhou
- Department of Gastic Surgery, Afiliated CancerHospital, Fudan University, Shanghai 200030, China
| | - Y B Zhou
- Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao 266003, China
| | - D Wu
- Department of Gastrointestinal Surgery, Second Affiliated Hospital, Zhejiang University, Hangzhou 310009, China
| | - X D Fang
- Department of Gastrointestinal Colorectal And Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China
| | - Y G Dai
- Department of Gastrointestinal Surgery, Yunnan Cancer Hospital, Kunming 650118, China
| | - H W Zhang
- Diagnosis and Treatment Center of Digestive Disease, Wuxi Mingci cardiovascular Hospital, Wuxi 214101, China
| | - J Q Cao
- Department of Gastrointestinal Surgery, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China
| | - L P Li
- Department of Gastrointestinal Surgery, The Affiliated Provincial Hospital, Shandong First Medical University, Jinan 250021, China
| | - J Chai
- Department of Gastric Surgery, The Affiliated Shandong Tumor Hospital, Shandong University, Jinan 250117, China
| | - K X Tao
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - G L Li
- Department of General Surgery, Jinling Hospital/General Hospital of Eastern Theater Command, School of Medicine, Nanjing University, Nanjing 210002, China
| | - Z G Jie
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - J Ge
- Department of Gastrointestinal Surgery Xiangya Hospital of Central South University, Changsha 410008, China
| | - Z F Xu
- Department of General Surgery, The Affiliated Hospital, Shandong Academy of Medical Sciences, Jinan 250031, China
| | - W B Zhang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - Q Y Li
- Departerment of Abdominal Surgery, Jiangxi Cancer Hospital, Nanchang 330029, China
| | - P Zhao
- Departerment of Gastrointestinal Surgery, Sichuan Tumor Hospital, Chengdu 610041, China
| | - Z Q Ma
- Department of General Surgery, Peking Uninon Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences (CAMS) and PUMC, Beijing 100730, China
| | - Z L Yan
- Department of Gastrointestinal Surgery, Ningbo First Hospital, Ningbo 315000, China
| | - G L Zheng
- Department of Gastric surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer Prevention and Therapy, Tianjin 300060, China
| | - Y Yan
- Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| | - X L Tang
- Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China
| | - X Zhou
- The Third Department of Surgery, The Fourth Hospital, Hebei Medical University, Shijiazhuang 050011, China
| |
Collapse
|
15
|
Yang C, Chen N, Tang XL, Qian XH, Cai CP. Immunomodulatory effects of IL-33 and IL-25 in an ovalbumin-induced allergic rhinitis mouse model. J BIOL REG HOMEOS AG 2021; 35:571-581. [PMID: 33738997 DOI: 10.23812/20-615-a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Both interleukin (IL)-33 and IL-25 induce Th2-type cytokine production by various cell types, suggesting that they may contribute to development of allergic disorders, however, the immunomodulatory effects of IL-33 and IL-25 in ovalbumin (OVA)-induced allergic rhinitis (AR) remain unclear. In the present study, anti-IL-33 and anti-IL-25 Abs were administrated intranasally during rechallenge in OVA-induced AR. Immunomodulatory effects were evaluated by measuring nasal rubbing, sneezing occurrence, serum OVA-specific antibodies, Th2 immune responses, neutrophil, eosinophil and mast cell recruitment into the nasal mucosa. We found that treatment with anti-IL-33 Ab markedly reduced nasal rubbing, sneezing events, Th2 immune responses, serum OVA-specific IgE and IgG1 levels, mucosal neutrophil, eosinophil and mast cell infiltration. In contrast, the effect of IL-25 antagonism was limited to attenuating the Th2 immune responses, and neutrophil and eosinophil infiltration. These observations indicate that IL-33 and IL-25 play a pathogenic role in an established AR mouse model, with a greater contribution of IL-33 than IL-25. Our findings suggest that IL-33 neutralization may be a potential approach for treatment of AR.
Collapse
Affiliation(s)
- C Yang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Huangpu District, Shanghai, China
| | - N Chen
- Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Huangpu District, Shanghai, China
| | - X L Tang
- School of Biomedical Engineering, Shanghai Jiao Tong University, Xuhui District, Shanghai, China
| | - X H Qian
- School of Biomedical Engineering, Shanghai Jiao Tong University, Xuhui District, Shanghai, China
| | - C P Cai
- Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Huangpu District, Shanghai, China
| |
Collapse
|
16
|
Kassem K, Abouleisa RR, Tang XL, Ou Q, Solanki M, Bolli R, Mohamed TM. PRECLINICAL EFFICACY STUDY IN A PORCINE MODEL FOR A NOVEL GENE THERAPY APPROACH TO PROMOTE CARDIOMYOCYTE PROLIFERATION IN ISCHEMIC CARDIOMYOPATHY. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)01373-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Bolli R, Tang XL, Guo Y, Li Q. After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease. Can J Physiol Pharmacol 2020; 99:129-139. [PMID: 32937086 DOI: 10.1139/cjpp-2020-0406] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The falsification of data related to c-kit+ cardiac progenitor cells (CPCs) by a Harvard laboratory has been a veritable tragedy. Does this fraud mean that CPCs are not beneficial in models of ischemic cardiomyopathy? At least 50 studies from 26 laboratories independent of the Harvard group have reported beneficial effects of CPCs in mice, rats, pigs, and cats. The mechanism of action remains unclear. Our group has shown that CPCs do not engraft in the diseased heart, do not differentiate into new cardiac myocytes, do not regenerate dead myocardium, and thus work via paracrine mechanisms. A casualty of the misconduct at Harvard has been the SCIPIO trial, a collaboration between the Harvard group and the group in Louisville. The retraction of the SCIPIO paper was caused exclusively by issues with data generated at Harvard, not those generated in Louisville. In the retraction notice, the Lancet editors stated: "Although we do not have any reservations about the clinical work in Louisville that used the preparations from Anversa's laboratory in good faith, the lack of reliability regarding the laboratory work at Harvard means that we are now retracting this paper". We must be careful not to dismiss all work on CPCs because of one laboratory's misconduct. An unbiased review of the literature supports the therapeutic potential of CPCs for heart failure at the preclinical level.
Collapse
Affiliation(s)
- Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA.,Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA.,Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| | - Yiru Guo
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA.,Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| | - Qianghong Li
- Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA.,Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, USA
| |
Collapse
|
18
|
Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA. Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity. Toxicol Appl Pharmacol 2020; 406:115213. [PMID: 32877659 DOI: 10.1016/j.taap.2020.115213] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/20/2020] [Accepted: 08/22/2020] [Indexed: 02/07/2023]
Abstract
The limited availability of human heart tissue and its complex cell composition are major limiting factors for the reliable testing of drug efficacy and toxicity. Recently, we developed functional human and pig heart slice biomimetic culture systems that preserve the viability and functionality of 300 μm heart slices for up to 6 days. Here, we tested the reliability of this culture system for testing the cardiotoxicity of anti-cancer drugs. We tested three anti-cancer drugs (doxorubicin, trastuzumab, and sunitinib) with known different mechanisms of cardiotoxicity at three concentrations and assessed the effect of these drugs on heart slice viability, structure, function and gene expression. Slices incubated with any of these drugs for 48 h showed diminished in viability as well as loss of cardiomyocyte structure and function. Mechanistically, RNA sequencing of doxorubicin-treated tissues demonstrated a significant downregulation of cardiac genes and upregulation of oxidative stress responses. Trastuzumab treatment downregulated cardiac muscle contraction-related genes consistent with its clinically known effect on cardiomyocytes. Interestingly, sunitinib treatment resulted in significant downregulation of angiogenesis-related genes, in line with its mechanism of action. Similar to hiPS-derived-cardiomyocytes, heart slices recapitulated the expected toxicity of doxorubicin and trastuzumab, however, slices were superior in detecting sunitinib cardiotoxicity and mechanism in the clinically relevant concentration range of 0.1-1 μM. These results indicate that heart slice culture models have the potential to become a reliable platform for testing and elucidating mechanisms of drug cardiotoxicity.
Collapse
Affiliation(s)
- Jessica M Miller
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA; Department of Bioengineering, University of Louisville, KY, USA
| | - Moustafa H Meki
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA; Department of Bioengineering, University of Louisville, KY, USA
| | - Qinghui Ou
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA
| | - Sharon A George
- Department of Biomedical Engineering, The George Washington University, Washington, DC, USA
| | - Anna Gams
- Department of Biomedical Engineering, The George Washington University, Washington, DC, USA
| | - Riham R E Abouleisa
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA
| | - Brooke M Ahern
- Department of Physiology, University of Kentucky, KY, USA
| | | | - Ayman El-Baz
- Department of Bioengineering, University of Louisville, KY, USA
| | - Bradford G Hill
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY, USA
| | - Jonathan Satin
- Department of Physiology, University of Kentucky, KY, USA
| | - Daniel J Conklin
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY, USA
| | - Javid Moslehi
- Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, USA
| | - Roberto Bolli
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA
| | - Alexandre J S Ribeiro
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Science, Office of Clinical Pharmacology, Division of Applied Regulatory Science, Silver Spring, MD, USA.
| | - Igor R Efimov
- Department of Biomedical Engineering, The George Washington University, Washington, DC, USA.
| | - Tamer M A Mohamed
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA; Department of Bioengineering, University of Louisville, KY, USA; Envirome Institute, Diabetes and Obesity Center, Department of Medicine, University of Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville, KY, USA; Institute of Cardiovascular Sciences, University of Manchester, UK; Faculty of Pharmacy, Zagazig University, Egypt.
| |
Collapse
|
19
|
Shen YL, Chen QH, Tang XL, Xu H, Li HM, Zhao SY. [Clinical features of cystic fibrosis associated allergic bronchopulmonary aspergillosis in children]. Zhonghua Er Ke Za Zhi 2020; 58:646-652. [PMID: 32842385 DOI: 10.3760/cma.j.cn112140-20200426-00435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Objective: To analyze the clinical features of cystic fibrosis (CF) associated allergic bronchopulmonary aspergillosis (ABPA) in children. Methods: A retrospective study was performed in 22 children who were diagnosed with CF associated ABPA in Beijing Children's Hospital affiliated to Capital Medical University from March 2010 to March 2020. The clinical features, imaging characteristics, laboratory results and the prognosis were reviewed. Results: A total of 22 cases met the diagnostic criterion, including 12 males and 10 females. The age of diagnosis was (10.4±2.8) years and the age of onset was (5.5±4.4) years. Clinical manifestations included cough and expectoration (22 cases), recurrent wheezing (15 cases), hemoptysis (7 cases), failure to thrive (12 cases), pancreatitis (10 cases), hepatomegaly (7 cases), splenomegaly (4 cases) and steatorrhea (4 cases). CT scans of all the patients showed pulmonary infiltrates and central bronchiectasis, combined with mucoid impaction in 17 cases and high density mucus plug in 12 cases. Eosinophilia was found in 18 patients. Total IgE and serum levels of A. fumigatus-specific IgE were elevated in all 22 patients. Positive culture of sputum or bronchoalvedar lauage fluid for fungus were in 15 cases, with single Aspergillus infection in 8 cases and mixed Aspergillus infection in 3 cases. The predominant bacteria found in the airways were Pseudomonas aeruginosa (17 cases), followed by staphylococcas. aureus (6 cases) and stenotrophomonas. maltophilia (5 cases). Pulmonary function revealed obstructive ventilation dysfunction in 4 cases, mixed dysfunction in 11 cases, and small airway dysfunction in 4 cases. Regarding the treatment, 3 were treated only with systemic corticosteroid, while the remaining 19 cases also received antifungal agents.The follow up continued for 1-7 years, and 6 maintained remission, 10 had recurrent episodes, 1 died, and 5 lost to follow up. Conclusions: CF associated ABPA is extremely rare in China. The overlapping clinical, radiographic, and immunologic features of these two diseases make the diagnosis challenging. Systemic corticosteroids are considered the first-line therapy for these patients, and adjuvant antifungal agents may be helpful. Recurrence rate in our center is high.
Collapse
Affiliation(s)
- Y L Shen
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - Q H Chen
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - X L Tang
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - H Xu
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - H M Li
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| | - S Y Zhao
- Department No. 2 of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
| |
Collapse
|
20
|
Ou Q, Abouleisa RRE, Tang XL, Juhardeen HR, Meki MH, Miller JM, Giridharan G, El-Baz A, Bolli R, Mohamed TMA. Slicing and Culturing Pig Hearts under Physiological Conditions. J Vis Exp 2020. [PMID: 32250357 DOI: 10.3791/60913] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Many novel drugs fail in clinical studies due to cardiotoxic side effects as the currently available in vitro assays and in vivo animal models poorly predict human cardiac liabilities, posing a multi-billion-dollar burden on the pharmaceutical industry. Hence, there is a worldwide unmet medical need for better approaches to identify drug cardiotoxicity before undertaking costly and time consuming 'first in man' trials. Currently, only immature cardiac cells (human induced pluripotent stem cell-derived cardiomyocytes [hiPSC-CMs]) are used to test therapeutic efficiency and drug toxicity as they are the only human cardiac cells that can be cultured for prolonged periods required to test drug efficacy and toxicity. However, a single cell type cannot replicate the phenotype of the complex 3D heart tissue which is formed of multiple cell types. Importantly, the effect of drugs needs to be tested on adult cardiomyocytes, which have different characteristics and toxicity responses compared to immature hiPSC-CMs. Culturing human heart slices is a promising model of intact human myocardium. This technology provides access to a complete multicellular system that mimics the human heart tissue and reflects the physiological or pathological conditions of the human myocardium. Recently, through optimization of the culture media components and the culture conditions to include continuous electrical stimulation at 1.2 Hz and intermittent oxygenation of the culture medium, we developed a new culture system setup that preserves viability and functionality of human and pig heart slices for 6 days in culture. In the current protocol, we are detailing the method for slicing and culturing pig heart as an example. The same protocol is used to culture slices from human, dog, sheep, or cat hearts. This culture system has the potential to become a powerful predictive human in situ model for acute cardiotoxicity testing that closes the gap between preclinical and clinical testing results.
Collapse
Affiliation(s)
- Qinghui Ou
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville
| | - Riham R E Abouleisa
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville
| | - Hamzah R Juhardeen
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville
| | | | | | | | - Ayman El-Baz
- Department of Bioengineering, University of Louisville
| | - Roberto Bolli
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville
| | - Tamer M A Mohamed
- Institute of Molecular Cardiology, Department of Medicine, University of Louisville; Diabetes and Obesity Center, Department of Medicine, University of Louisville; Department of Pharmacology and Toxicology, University of Louisville; Institute of Cardiovascular Sciences, University of Manchester; Faculty of Pharmacy, Zagazig University;
| |
Collapse
|
21
|
Ke RD, Tang AZ, Tang XL, Gong L, Fang Q, Tan SH. [Clinical application of HRCT three-dimensional reconstruction in traumatic ossicular chain interruption]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 33:1129-1133. [PMID: 31914258 DOI: 10.13201/j.issn.1001-1781.2019.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Indexed: 11/12/2022]
Abstract
Objective:To investigate the clinical value of HRCT three-dimensional reconstruction technique in traumatic auditory chain traumatic fracture. Method:The clinical data of 14 patients with traumatic ear ossicular chain interruption were analyzed retrospectively. To evaluate the injury site and degree of the auditory chain before surgery, all the 14 patients underwent,HRCT scanning and three-dimensional reconstruction. The reconstructed auditory chain was observed from multiple angles and compared with the surgical exploration results under microscope. Result:The coincidence rate between ossicular chain injury observed by temporal bone HRCT scan before operation and ossicular chain injury observed during surgery was only 28.57%, the coincidence rate between ossicular chain injury observed during surgery and ossicular chain injury observed by three-dimensional reconstruction is 85.71%.Therefore, three-dimensional reconstruction imaging technique could give the doctor more clearly and stereoscopic images for the destruction of ossicular chain. Conclusion:Preoperative three-dimensional reconstruction can display and diagnosis of auditory ossicular chain destruction more clearly. It can be used to accurately evaluate auditory ossicular chain pathological changes, to develop individualized surgical plans and assess the risk of surgery.
Collapse
Affiliation(s)
- R D Ke
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| | - A Z Tang
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| | - X L Tang
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| | - L Gong
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| | - Q Fang
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| | - S H Tan
- Department of Otolaryngology Head and Neck Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning,530021,China
| |
Collapse
|
22
|
Heidel JS, Fischer AG, Tang XL, Sadri G, Wu WJ, Moisa CR, Stowers H, Sandella N, Wysoczynski M, Uchida S, Moore IV JB. The Effect of Cardiogenic Factors on Cardiac Mesenchymal Cell Anti-Fibrogenic Paracrine Signaling and Therapeutic Performance. Am J Cancer Res 2020; 10:1514-1530. [PMID: 32042319 PMCID: PMC6993223 DOI: 10.7150/thno.41000] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 11/12/2019] [Indexed: 12/20/2022] Open
Abstract
Intrinsic cardiogenic factor expression, a proxy for cardiomyogenic lineage commitment, may be an important determinant of donor cell cardiac reparative capacity in cell therapy applications; however, whether and how this contributes to their salutary effects remain largely ambiguous. Methods: The current study examined the consequences of enhanced cardiogenic factor expression, via lentiviral delivery of GMT (GATA4, MEF2C, and TBX5), on cardiac mesenchymal cell (CMC) anti-fibrogenic paracrine signaling dynamics, in vitro, and cardiac reparative capacity, in vivo. Proteome cytokine array analyses and in vitro cardiac fibroblast activation assays were performed using conditioned medium derived from either GMT- or GFP control-transduced CMCs, to respectively assess cardiotrophic factor secretion and anti-fibrogenic paracrine signaling aptitude. Results: Relative to GFP controls, GMT CMCs exhibited enhanced secretion of cytokines implicated to function in pathways associated with matrix remodeling and collagen catabolism, and more ably impeded activated cardiac fibroblast Col1A1 synthesis in vitro. Following their delivery in a rat model of chronic ischemic cardiomyopathy, conventional echocardiography was unable to detect a therapeutic advantage with either CMC population; however, hemodynamic analyses identified a modest, yet calculable supplemental benefit in surrogate measures of global left ventricular contractility with GMT CMCs relative to GFP controls. This phenomenon was neither associated with a decrease in infarct size nor an increase in viable myocardium, but with only a marginal decrease in regional myocardial collagen deposition. Conclusion: Overall, these results suggest that CMC cardiomyogenic lineage commitment biases cardiac repair and, further, that enhanced anti-fibrogenic paracrine signaling potency may underlie, in part, their improved therapeutic utility.
Collapse
|
23
|
Abouleisa R, Ou Q, Jacobson Z, Tang XL, Hindi SM, Kumar A, Ivey KN, Giridharan G, Al-Baz A, Brittian K, Rood B, Hill BG, Jones SP, Bolli R, Mohamed TM. Abstract 208: Reliable Biomimetic Culture System for Pig and Human Heart Slices. Circ Res 2019. [DOI: 10.1161/res.125.suppl_1.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rationale:
Heart failure is the number one killer and drug induced cardiotoxicity is a major cause of market withdrawal. The lack of availability of culture systems for human heart tissue that is functionally and structurally viable for more than 24 hours is a limiting factor in validation of novel heart failure therapies as well as reliable cardiotoxicity testing. Therefore, there is an urgent need to develop a reliable system for culturing human heart tissue for testing drug efficacy and toxicity.
Objective:
To develop a reliable method to culture pig and human heart slices under full physiological conditions for a period of time sufficient to test therapeutic efficacy and acute drug toxicity.
Methods and Results:
Here we describe a novel biomimetic culture system that maintains full viability and functionality of human and pig heart slices (300 μm thickness) for 6 days in culture through optimization of the medium and culture conditions with continuous electrical stimulation at 1.2 Hz and oxygenation of the medium. Functional viability of these slices over 6 days was confirmed by assessing their calcium homeostasis, twitch force generation, and response to β-adrenergic stimulation. Temporal transcriptome analysis using RNAseq at day 2, 6, and 10 in culture confirmed overall maintenance of normal gene expression for up to 6 days, while over 500 transcripts were differentially regulated after 10 days. Electron microscopy demonstrated intact mitochondria and Z-disc ultra-structures after 6 days in culture under our optimized conditions. This biomimetic culture system was successful in keeping human heart slices completely viable and functionally and structurally intact for 6 days in culture. We also used this system to demonstrate the effects of a novel gene therapy approach in human heart slices.
Conclusions:
We have developed and optimized a reliable and easily reproducible culture system for pig and human heart slices as a platform for testing the efficacy of novel heart failure therapeutics as well as reliable testing of cardiotoxicity in a 3D heart model.
Collapse
|
24
|
Tang XL, Yang HM, Liu H, Xu H, Zhou CJ, Li HM, Zhao SY, Liu JR. [Clinical analysis of methylmalonic acidemia and hyperhomocysteinemia with diffuse lung disease as an initial or main presentation]. Zhonghua Er Ke Za Zhi 2019; 57:620-624. [PMID: 31352748 DOI: 10.3760/cma.j.issn.0578-1310.2019.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To improve the awareness of methylmalonic acidemia and hyperhomocysteinemia with diffuse lung disease as an initial or main presentation. Methods: A retrospective analysis of the clinical manifestations, radiological features, laboratory tests, genetic variations, treatments and prognoses was conducted in six children presented with diffuse lung disease and finally diagnosed with methylmalonic acidemia and hyperhomocysteinemia in Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, from August 2017 to November 2018. Results: Six children were included in this study. Two children were male and four were female. The average age of onset was 28 months. The mean age at diagnosis was 34 months. The average interval from onset to diagnosis was 6 months. Four children who underwent genetic tests were found to have variants of gene MMACHC and diagnosed with CblC type. All children had respiratory symptoms and signs as initial or main presentation, which were tachypnea (5 cases), exercise intolerance (5 cases), cough (4 cases), cyanosis (4 cases), clubbing (4 cases), dyspnea (3 cases) and retractions (3 cases). Pulmonary arterial hypertension was found in all six children. Pericardial effusion (4 cases), kidney involvement (3 cases), nervous system involvement (3 cases), gastrointestinal system involvement (3 cases) and anemia (2 cases) also coexisted. The high resolution computed tomography (HRCT) features included dilated pulmonary artery (6 cases), ground-glass opacities (4 cases), diffuse poorly defined ground-glass centrilobular nodules (3 cases), pleural effusion (3 cases), thickening of interlobular septum (2 cases), etc. All children had an elevated concentration of methylmalonic acid in urine and homocysteine in plasma. Genetic tests were performed in four patients, and MMACHC genetic mutations were found in all of them. Clinical manifestations, HRCT features and pulmonary arterial hypertension turned better in five children after treatment. One patient who was not regularly followed-up died. Conclusions: Pulmonary involvement including diffuse lung disease and pulmonary arterial hypertension could coexist with methylmalonic acidemia and hyperhomocysteinemia, which may have respiratory symptoms and signs as the initial or main presentation. Characteristic HRCT features were found in some patients. Plasma homocysteine test is a quick method for screening the disease in children with diffuse lung disease and (or) pulmonary arterial hypertension. Both diffuse lung disease and pulmonary arterial hypertension may turn better after treatment.
Collapse
Affiliation(s)
- X L Tang
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - H M Yang
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - H Liu
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - H Xu
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - C J Zhou
- Department of Pathology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - H M Li
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - S Y Zhao
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - J R Liu
- Ward 2 of Department of Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| |
Collapse
|
25
|
Ou Q, Jacobson Z, Abouleisa RRE, Tang XL, Hindi SM, Kumar A, Ivey KN, Giridharan G, El-Baz A, Brittian K, Rood B, Lin YH, Watson SA, Perbellini F, McKinsey TA, Hill BG, Jones SP, Terracciano CM, Bolli R, Mohamed TMA. Physiological Biomimetic Culture System for Pig and Human Heart Slices. Circ Res 2019; 125:628-642. [PMID: 31310161 DOI: 10.1161/circresaha.119.314996] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
RATIONALE Preclinical testing of cardiotoxicity and efficacy of novel heart failure therapies faces a major limitation: the lack of an in situ culture system that emulates the complexity of human heart tissue and maintains viability and functionality for a prolonged time. OBJECTIVE To develop a reliable, easily reproducible, medium-throughput method to culture pig and human heart slices under physiological conditions for a prolonged period of time. METHODS AND RESULTS Here, we describe a novel, medium-throughput biomimetic culture system that maintains viability and functionality of human and pig heart slices (300 µm thickness) for 6 days in culture. We optimized the medium and culture conditions with continuous electrical stimulation at 1.2 Hz and oxygenation of the medium. Functional viability of these slices over 6 days was confirmed by assessing their calcium homeostasis, twitch force generation, and response to β-adrenergic stimulation. Temporal transcriptome analysis using RNAseq at day 2, 6, and 10 in culture confirmed overall maintenance of normal gene expression for up to 6 days, while over 500 transcripts were differentially regulated after 10 days. Electron microscopy demonstrated intact mitochondria and Z-disc ultra-structures after 6 days in culture under our optimized conditions. This biomimetic culture system was successful in keeping human heart slices completely viable and functionally and structurally intact for 6 days in culture. We also used this system to demonstrate the effects of a novel gene therapy approach in human heart slices. Furthermore, this culture system enabled the assessment of contraction and relaxation kinetics on isolated single myofibrils from heart slices after culture. CONCLUSIONS We have developed and optimized a reliable medium-throughput culture system for pig and human heart slices as a platform for testing the efficacy of novel heart failure therapeutics and reliable testing of cardiotoxicity in a 3-dimensional heart model.
Collapse
Affiliation(s)
- Qinghui Ou
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY
| | - Zoë Jacobson
- Tenaya Therapeutics, South San Francisco, CA (Z.J., K.N.I.)
| | - Riham R E Abouleisa
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY
| | - Xian-Liang Tang
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY
| | - Sajedah M Hindi
- Departments of Anatomical Sciences and Neurobiology (S.M.H., A.K.), University of Louisville, KY
| | - Ashok Kumar
- Departments of Anatomical Sciences and Neurobiology (S.M.H., A.K.), University of Louisville, KY
| | - Kathryn N Ivey
- Tenaya Therapeutics, South San Francisco, CA (Z.J., K.N.I.)
| | | | - Ayman El-Baz
- Department of Bioengineering (G.G., A.E.-B.), University of Louisville, KY
| | - Kenneth Brittian
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY
| | - Benjamin Rood
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine (B.R., B.G.H., S.P.J., T.M.A.M.), University of Louisville, KY
| | - Ying-Hsi Lin
- Division of Cardiology and Consortium for Fibrosis Research & Translation, Department of Medicine, University of Colorado, Aurora (Y.-H.L., T.A.M.)
| | - Samuel A Watson
- National Heart & Lung Institute, Imperial College London, United Kingdom (S.A.W., F.P., C.M.T.)
| | - Filippo Perbellini
- National Heart & Lung Institute, Imperial College London, United Kingdom (S.A.W., F.P., C.M.T.).,Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (F.P.)
| | - Timothy A McKinsey
- Division of Cardiology and Consortium for Fibrosis Research & Translation, Department of Medicine, University of Colorado, Aurora (Y.-H.L., T.A.M.)
| | - Bradford G Hill
- Envirome Institute, Diabetes and Obesity Center, Department of Medicine (B.R., B.G.H., S.P.J., T.M.A.M.), University of Louisville, KY
| | - Steven P Jones
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY.,Envirome Institute, Diabetes and Obesity Center, Department of Medicine (B.R., B.G.H., S.P.J., T.M.A.M.), University of Louisville, KY
| | - Cesare M Terracciano
- National Heart & Lung Institute, Imperial College London, United Kingdom (S.A.W., F.P., C.M.T.)
| | - Roberto Bolli
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY
| | - Tamer M A Mohamed
- From the Department of Medicine, Institute of Molecular Cardiology (Q.O., R.R.E.A., X.-L.T., K.B., S.P.J., R.B., T.M.A.M.), University of Louisville, KY.,Envirome Institute, Diabetes and Obesity Center, Department of Medicine (B.R., B.G.H., S.P.J., T.M.A.M.), University of Louisville, KY.,Department of Pharmacology and Toxicology (T.M.A.M.), University of Louisville, KY.,Institute of Cardiovascular Sciences, University of Manchester, United Kingdom (T.M.A.M.).,Faculty of Pharmacy, Zagazig University, Egypt (T.M.A.M.)
| |
Collapse
|
26
|
Cai C, Teng L, Vu D, He JQ, Guo Y, Li Q, Tang XL, Rokosh G, Bhatnagar A, Bolli R. Correction: The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-related kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem 2019; 294:4725-4727. [PMID: 30902920 DOI: 10.1074/jbc.aac119.008182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
27
|
Wang X, Jin QJ, Jin QL, Sun W, Zhou YQ, Tang XL, Yin H. [A study on the pedigree of the academic inheritance of Li Shicai]. Zhonghua Yi Shi Za Zhi 2019; 49:55-60. [PMID: 30970426 DOI: 10.3760/cma.j.issn.0255-7053.2019.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Li Shicai, a famous physician of Ming Dynasty had a large number of students. Shen Langzhong, who was a student of Li Shicai, was the teacher of Ma Yuanyi, and one of Ma's student was You Zaijing. This inheritance pedigree was called "Li Shicai School" in academic communities. There were little of study on its later physicians after You Zaijing. This paper collated the medical works, genealogy, local chronicles and medical records of Li Shicai and doctors of different generations. We clarified the academic inheritance genealogy of the past four hundred years. Up to now, there have been twelve generations totally.
Collapse
Affiliation(s)
- X Wang
- The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| | - Q J Jin
- Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| | - Q L Jin
- Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| | - W Sun
- Nephrology Department, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
| | - Y Q Zhou
- Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| | - X L Tang
- Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| | - H Yin
- Shicai School Inherited Studio, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
| |
Collapse
|
28
|
Gong L, Tang XL, Liu YK, Liu YL, Zhou WW, Xia W, Tang AZ. [Research on the factors affecting the postoperative outcome of otosclerosis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 32:1922-1926. [PMID: 30550142 DOI: 10.13201/j.issn.1001-1781.2018.24.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Indexed: 11/12/2022]
Abstract
Summary Otosclerosis is not often seen in the clinic, but it can seriously affect the quality of life due to the hearing loss of patients. Currently, the treatment of otosclerosis is mainly surgery. With the development of microsurgical techniques, the treatment of surgery for otosclerosis has been highly praised and widely carried out. However, different surgical methods, assistive techniques and instruments used during surgery, selected placement of prostheses, and varying levels of experience of the surgeon can all affect postoperative outcomes. In order to provide reference for the surgical treatment of otosclerosis in the future,this paper will summarize the factors related to postoperative efficacy of stapes surgery for otosclerosis.
Collapse
|
29
|
Moore JB, Tang XL, Zhao J, Fischer AG, Wu WJ, Uchida S, Gumpert AM, Stowers H, Wysoczynski M, Bolli R. Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy. Basic Res Cardiol 2018; 114:3. [PMID: 30446837 DOI: 10.1007/s00395-018-0710-1] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 10/31/2018] [Indexed: 01/01/2023]
Abstract
Preclinical investigations support the concept that donor cells more oriented towards a cardiovascular phenotype favor repair. In light of this philosophy, we previously identified HDAC1 as a mediator of cardiac mesenchymal cell (CMC) cardiomyogenic lineage commitment and paracrine signaling potency in vitro-suggesting HDAC1 as a potential therapeutically exploitable target to enhance CMC cardiac reparative capacity. In the current study, we examined the effects of pharmacologic HDAC1 inhibition, using the benzamide class 1 isoform-selective HDAC inhibitor entinostat (MS-275), on CMC cardiomyogenic lineage commitment and CMC-mediated myocardial repair in vivo. Human CMCs pre-treated with entinostat or DMSO diluent control were delivered intramyocardially in an athymic nude rat model of chronic ischemic cardiomyopathy 30 days after a reperfused myocardial infarction. Indices of cardiac function were assessed by echocardiography and left ventricular (LV) Millar conductance catheterization 35 days after treatment. Compared with naïve CMCs, entinostat-treated CMCs exhibited heightened capacity for myocyte-like differentiation in vitro and superior ability to attenuate LV remodeling and systolic dysfunction in vivo. The improvement in CMC therapeutic efficacy observed with entinostat pre-treatment was not associated with enhanced donor cell engraftment, cardiomyogenesis, or vasculogenesis, but instead with more efficient inhibition of myocardial fibrosis and greater increase in myocyte size. These results suggest that HDAC inhibition enhances the reparative capacity of CMCs, likely via a paracrine mechanism that improves ventricular compliance and contraction and augments myocyte growth and function.
Collapse
Affiliation(s)
- Joseph B Moore
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA.
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - John Zhao
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Annalara G Fischer
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Wen-Jian Wu
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Shizuka Uchida
- Department of Medicine, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY, USA
| | - Anna M Gumpert
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Heather Stowers
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Marcin Wysoczynski
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| | - Roberto Bolli
- Institute of Molecular Cardiology, Division of Cardiovascular Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40292, USA
| |
Collapse
|
30
|
Tang XL, Li Y, Jia LF, Yuan W. [MicroRNA and sensorineural hearing loss]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 32:1523-1526. [PMID: 30550205 DOI: 10.13201/j.issn.1001-1781.2018.19.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Indexed: 11/12/2022]
Abstract
Hearing loss caused by disorders throughout the cochlea or auditory pathway called sensorineural hearing loss. The etiology of sensorineural deafness is complex and diverse, and the sensory epithelial cell damage of the inner ear spiral is the main pathological change. MicroRNAs play a role in the regulation of gene expression by inhibiting or degrading the mRNA of target genes. More and more studies have shown that microRNA plays an important role in the development of sensorineural deafness. This article will review the process of microRNA involvement in the development of sensorineural hearing loss.
Collapse
|
31
|
Han F, Liu H, Tang XL. [Langerhans cell histiocytosis with spontaneous pneumothorax as the first symptom]. Zhonghua Er Ke Za Zhi 2018; 56:383-384. [PMID: 29783829 DOI: 10.3760/cma.j.issn.0578-1310.2018.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
32
|
Tang XL, Nakamura S, Li Q, Wysoczynski M, Gumpert AM, Wu WJ, Hunt G, Stowers H, Ou Q, Bolli R. Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose. J Am Heart Assoc 2018; 7:JAHA.117.007400. [PMID: 29440036 PMCID: PMC5850187 DOI: 10.1161/jaha.117.007400] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND We have recently found that 3 repeated doses (12×106 each) of c-kitPOS cardiac progenitor cells (CPCs) were markedly more effective than a single dose of 12×106 cells in alleviating postinfarction left ventricular dysfunction and remodeling. However, since the single-dose group received only one third of the total number of CPCs given to the multiple-dose group, it is unknown whether the superior therapeutic efficacy was caused by repeated treatments per se or by administration of a higher total number of CPCs. This issue has major clinical implications because multiple cell injections in patients pose significant challenges, which would be obviated by using 1 large injection. Accordingly, we determined whether the beneficial effects of 3 repeated CPC doses can be recapitulated by 1 large dose containing the same total number of cells. METHODS AND RESULTS Rats with a 30-day-old myocardial infarction received 3 echo-guided intraventricular infusions, 35 days apart, of vehicle-vehicle-vehicle, 36×106 CPCs-vehicle-vehicle, or 3 equal doses of 12×106 CPCs. Infusion of a single, large dose of CPCs (36×106 cells) produced an initial improvement in left ventricular function, but no further improvement was observed after the second and third infusions (both vehicle). In contrast, each of the 3 doses of CPCs (12×106) caused a progressive improvement in left ventricular function, the cumulative magnitude of which was greater than with a single dose. Unlike the single dose, repeated doses reduced collagen content and immune cell infiltration. CONCLUSIONS Three repeated doses of CPCs are superior to 1 dose even though the total number of cells infused is the same, possibly because of greater antifibrotic and anti-inflammatory actions.
Collapse
Affiliation(s)
- Xian-Liang Tang
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Shunichi Nakamura
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Qianhong Li
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Marcin Wysoczynski
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Anna M Gumpert
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Wen-Jian Wu
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Greg Hunt
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Heather Stowers
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Qinghui Ou
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| | - Roberto Bolli
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY
| |
Collapse
|
33
|
Liu H, Tang XL, Liu JR, Li HM, Zhao SY. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation]. Zhonghua Er Ke Za Zhi 2017; 54:698-702. [PMID: 27596086 DOI: 10.3760/cma.j.issn.0578-1310.2016.09.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To analyze clinical and genetic features of activated PI3K-δ syndrome (APDS), a new form of immunodeficiency disease caused by PIK3CD gene mutation. METHOD Data of two patients diagnosed as APDS at Second Department of Respiratory Medicine of Beijing Children's Hospital Affiliated to Capital Medical University in 2015 were retrospectively reviewed. Pathogenetic genes were screened by whole exome sequencing, and identified by first generation sequencing. The identified pathogenetic genes were further verified in patients' parents. Then the gene sequencing results were analyzed. RESULT Both patients were females, aged 2 years and 4 months and 5 years respectively. The main clinical features of both cases were recurrent respiratory infections, enlargement of lymph node, hepatosplenomegaly, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) viremia, decreased number of native CD4(+) T cell, inverted CD4(+) /CD8(+) T cell ratio and increased IgM. Patient 1 has decreased IgA and IgG. Patient 2 showed wide follicular hyperplasia of the airway mucosa. Both patients had de novo mutation in c. 3061G>A(E1021K)of PIK3CD gene, which was homozygous in patient 1 and heterozygous in patient 2. Both were treated with 500 mg/kg dose of gamma globulin intravenously at 4-weeks interval. Patient 1 started oral rapamycin therapy at the dose of 1 mg/(m(2)·d) and discontinued the treatment after 2 weeks. Patient 2 was given low dose of oral prednisone. The two patients were followed up for 2 months. The number of respiratory infection in both patients was decreased. Hepatosplenomegaly was subsided, while respiratory tract damage was not improved in patient 2. CONCLUSION The clinical manifestations of APDS include recurrent respiratory tract infection, enlargement of lymph nodes, hepatosplenomegaly, and CMV or EBV infection. The immunophenotype is decreased native CD4(+) T cell, inverted CD4(+) /CD8(+) T cell ratio, increased IgM and decreased IgA/IgG for some patients. c. 3061G>A(E1021K)of PIK3CD gene is a common de novo mutation in APDS patients.
Collapse
Affiliation(s)
- H Liu
- Second Department of Respiratory Medicine, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China
| | | | | | | | | |
Collapse
|
34
|
Wysoczynski M, Guo Y, Moore JB, Muthusamy S, Li Q, Nasr M, Li H, Nong Y, Wu W, Tomlin AA, Zhu X, Hunt G, Gumpert AM, Book MJ, Khan A, Tang XL, Bolli R. Myocardial Reparative Properties of Cardiac Mesenchymal Cells Isolated on the Basis of Adherence. J Am Coll Cardiol 2017; 69:1824-1838. [PMID: 28385312 DOI: 10.1016/j.jacc.2017.01.048] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2016] [Revised: 01/10/2017] [Accepted: 01/20/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND The authors previously reported that the c-kit-positive (c-kitPOS) cells isolated from slowly adhering (SA) but not from rapidly adhering (RA) fractions of cardiac mesenchymal cells (CMCs) are effective in preserving left ventricular (LV) function after myocardial infarction (MI). OBJECTIVES This study evaluated whether adherence to plastic alone, without c-kit sorting, was sufficient to isolate reparative CMCs. METHODS RA and SA CMCs were isolated from mouse hearts, expanded in vitro, characterized, and evaluated for therapeutic efficacy in mice subjected to MI. RESULTS Morphological and phenotypic analysis revealed that murine RA and SA CMCs are indistinguishable; nevertheless, transcriptome analysis showed that they possess fundamentally different gene expression profiles related to factors that regulate post-MI LV remodeling and repair. A similar population of SA CMCs was isolated from porcine endomyocardial biopsy samples. In mice given CMCs 2 days after MI, LV ejection fraction 28 days later was significantly increased in the SA CMC group (31.2 ± 1.0% vs. 24.7 ± 2.2% in vehicle-treated mice; p < 0.05) but not in the RA CMC group (24.1 ± 1.2%). Histological analysis showed reduced collagen deposition in the noninfarcted region in mice given SA CMCs (7.6 ± 1.5% vs. 14.5 ± 2.8% in vehicle-treated mice; p < 0.05) but not RA CMCs (11.7 ± 1.7%), which was associated with reduced infiltration of inflammatory cells (14.1 ± 1.6% vs. 21.3 ± 1.5% of total cells in vehicle and 19.3 ± 1.8% in RA CMCs; p < 0.05). Engraftment of SA CMCs was negligible, which implies a paracrine mechanism of action. CONCLUSIONS We identified a novel population of c-kit-negative reparative cardiac cells (SA CMCs) that can be isolated with a simple method based on adherence to plastic. SA CMCs exhibited robust reparative properties and offered numerous advantages, appearing to be more suitable than c-kitPOS cardiac progenitor cells for widespread clinical therapeutic application.
Collapse
Affiliation(s)
- Marcin Wysoczynski
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky; Diabetes and Obesity Center, University of Louisville School of Medicine, Louisville, Kentucky.
| | - Yiru Guo
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Joseph B Moore
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Senthilkumar Muthusamy
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Qianhong Li
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Marjan Nasr
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Hong Li
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Yibing Nong
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Wenjian Wu
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Alex A Tomlin
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Xiaoping Zhu
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Gregory Hunt
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Anna M Gumpert
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Michael J Book
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Abdur Khan
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky
| | - Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky; Diabetes and Obesity Center, University of Louisville School of Medicine, Louisville, Kentucky.
| |
Collapse
|
35
|
Li XT, Wang Y, Lu SS, Li M, Men SK, Bai YC, Tang XL, Chen Q. The Cold Hardiness of Phrynocephalus erythrurus, the Lizard Living at Highest Altitude in the World. Cryo Letters 2017; 38:216-227. [PMID: 28767745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND Phrynocephalus erythrurus living at Qinghai-Tibet Plateau, is believed to be the highest lizard in the world, but we know little about how these lizards cope with very low temperatures in winter. OBJECTIVE The aim of this study was to find the difference of the lizards before and after cold acclimatization. MATERIALS AND METHODS In this study the limit of supercooling and inoculative freezing, the concentration of four organic osmolytes, and the activity of lactate dehydrogenase in the plasma were measured in samples shortly after capture and in other samples after 7~8 weeks of acclimatization at 2~4 degree C. RESULTS Animals acquired an ability to undergo deeper supercooling and inoculative freezing through the course of acclimatization. We find no regular changes of the four organic osmolytes after the acclimatization. CONCLUSION We think that this species of lizard is partly freeze-tolerant and conclude that it uses supercooling to survive in winter.
Collapse
Affiliation(s)
- X T Li
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - Y Wang
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - S S Lu
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - M Li
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - S K Men
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - Y C Bai
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - X L Tang
- School of Life Sciences, Lanzhou University, Lanzhou, China
| | - Q Chen
- School of Life Sciences, Lanzhou University, Lanzhou, China.
| |
Collapse
|
36
|
Tokita Y, Tang XL, Li Q, Wysoczynski M, Hong KU, Nakamura S, Wu WJ, Xie W, Li D, Hunt G, Ou Q, Stowers H, Bolli R. Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy. Circ Res 2016; 119:635-51. [PMID: 27364016 DOI: 10.1161/circresaha.116.308937] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 06/30/2016] [Indexed: 12/28/2022]
Abstract
RATIONALE The effects of c-kit(POS) cardiac progenitor cells (CPCs, and adult cell therapy in general) on left ventricular (LV) function have been regarded as modest or inconsistent. OBJECTIVE To determine whether 3 CPC infusions have greater efficacy than 1 infusion. METHODS AND RESULTS Rats with a 30-day-old myocardial infarction received 1 or 3 CPC infusions into the LV cavity, 35 days apart. Compared with vehicle-treated rats, the single-dose group exhibited improved LV function after the first infusion (consisting of CPCs) but not after the second and third (vehicle). In contrast, in the multiple-dose group, regional and global LV function improved by a similar degree after each CPC infusion, resulting in greater cumulative effects. For example, the total increase in LV ejection fraction was approximately triple in the multiple-dose group versus the single-dose group (P<0.01). The multiple-dose group also exhibited more viable tissue and less scar, less collagen in the risk and noninfarcted regions, and greater myocyte density in the risk region. CONCLUSIONS This is the first demonstration that repeated CPC administrations are markedly more effective than a single administration. The concept that the full effects of CPCs require repeated doses has significant implications for both preclinical and clinical studies; it suggests that the benefits of cell therapy may be underestimated or even overlooked if they are measured after a single dose, and that repeated administrations are necessary to evaluate the effectiveness of a cell product properly. In addition, we describe a new method that enables studies of repeated cell administrations in rodents.
Collapse
Affiliation(s)
- Yukichi Tokita
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Xian-Liang Tang
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Qianhong Li
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Marcin Wysoczynski
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Kyung U Hong
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Shunichi Nakamura
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Wen-Jian Wu
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Wei Xie
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Ding Li
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Greg Hunt
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Qinghui Ou
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Heather Stowers
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Roberto Bolli
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY.
| |
Collapse
|
37
|
Yao ZX, Tang AZ, Xie M, He GY, Tang XL. [Current diagnosis and treatment of pseudoaneurysms of the internal carotid artery in postirradiated nasopharyngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016; 30:919-921. [PMID: 29797944 DOI: 10.13201/j.issn.1001-1781.2016.11.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Indexed: 11/12/2022]
Abstract
Nasopharyngeal carcinoma is one of the most common of head and neck malignant tumors in southern region of China. Till date radiotherapy is considered as the first choice of treatment this disease.Although the rate of occurrence of pseudoaneurysms of the internal carotid artery in post radiation treatment of nasopharyngeal carcinoma is low, it is also a hot topic in department of otolaryngology and doctors because of its dangerous and lifethreatening emergencies.In order to improve the level of diagnosis and treatment of the disease, diagnosis, risk, treatment, prognosis and prevention are current summarized in this report.
Collapse
|
38
|
Chen M, Liu XH, Tang XL. [Methamphetamine-associated cardiomyopathy: a case report]. Zhonghua Xin Xue Guan Bing Za Zhi 2016; 44:352-353. [PMID: 27112617 DOI: 10.3760/cma.j.issn.0253-3758.2016.04.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
39
|
Tang XL, Li Q, Rokosh G, Sanganalmath SK, Chen N, Ou Q, Stowers H, Hunt G, Bolli R. Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year. Circ Res 2016; 118:1091-105. [PMID: 26838790 DOI: 10.1161/circresaha.115.307647] [Citation(s) in RCA: 114] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 02/02/2016] [Indexed: 12/16/2022]
Abstract
RATIONALE Cardiac progenitor cells (CPCs) improve left ventricular remodeling and function after acute or chronic myocardial infarction. However, the long-term (>5 weeks) effects, potential tumorigenicity, and fate of transplanted CPCs are unknown. OBJECTIVE To assess the outcome of CPC therapy at 1 year. METHODS AND RESULTS Female rats underwent a 90-minute coronary occlusion; 4 hours after reperfusion, they received intracoronarily vehicle or 1 million male, syngeneic CPCs. One year later, CPC-treated rats exhibited smaller scars and more viable myocardium in the risk region, along with improved left ventricular remodeling and regional and global left ventricular function. No tumors were observed. Some transplanted (Y-chromosome(POS)) CPCs (or their progeny) persisted and continued to proliferate, but they failed to acquire a mature cardiomyocyte phenotype and were too few (4-8% of nuclei) to account for the benefits of CPC therapy. Surprisingly, CPC transplantation triggered a prolonged proliferative response of endogenous cells, resulting in increased formation of endothelial cells and Y-chromosome(NEG) CPCs for 12 months and increased formation, for at least 7 months, of small cells that expressed cardiomyocytic proteins (α-sarcomeric actin) but did not have a mature cardiomyocyte phenotype. CONCLUSIONS The beneficial effects of CPCs on left ventricular remodeling and dysfunction are sustained for at least 1 year and thus are likely to be permanent. Because transplanted CPCs do not differentiate into mature myocytes, their major mechanism of action must involve paracrine actions. These paracrine mechanisms could be very prolonged because some CPCs engraft, proliferate, and persist at 1 year. This is the first report that transplantation of any cell type in the heart induces a proliferative response that lasts at least 1 year. The results strongly support the safety and clinical utility of CPC therapy.
Collapse
Affiliation(s)
- Xian-Liang Tang
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Qianhong Li
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Gregg Rokosh
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Santosh K Sanganalmath
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Ning Chen
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Qinghui Ou
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Heather Stowers
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Greg Hunt
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY
| | - Roberto Bolli
- From the Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY.
| |
Collapse
|
40
|
Keith MCL, Tokita Y, Tang XL, Ghafghazi S, Moore JB, Hong KU, Elmore JB, Amraotkar AR, Guo H, Ganzel BL, Grubb KJ, Flaherty MP, Vajravelu BN, Wysoczynski M, Bolli R. Effect of the stop-flow technique on cardiac retention of c-kit positive human cardiac stem cells after intracoronary infusion in a porcine model of chronic ischemic cardiomyopathy. Basic Res Cardiol 2015; 110:503. [PMID: 26150250 DOI: 10.1007/s00395-015-0503-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 06/05/2015] [Accepted: 06/15/2015] [Indexed: 01/03/2023]
Abstract
It is commonly thought that the optimal method for intracoronary administration of cells is to stop coronary flow during cell infusion, in order to prolong cell/vascular wall contact, enhance adhesion, and promote extravasation of cells into the interstitial space. However, occlusion of a coronary artery with a balloon involves serious risks of vascular damage and/or dissection, particularly in non-stented segments such as those commonly found in patients with heart failure. It remains unknown whether the use of the stop-flow technique results in improved donor cell retention. Acute myocardial infarction was produced in 14 pigs. One to two months later, pigs received 10 million indium-111 oxyquinoline (oxine)-labeled c-kit(pos) human cardiac stem cells (hCSCs) via intracoronary infusion with (n = 7) or without (n = 7) balloon inflation. Pigs received cyclosporine to prevent acute graft rejection. Animals were euthanized 24 h later and hearts harvested for radioactivity measurements. With the stop-flow technique, the retention of hCSCs at 24 h was 5.41 ± 0.80 % of the injected dose (n = 7), compared with 4.87 ± 0.62 % without coronary occlusion (n = 7), (P = 0.60). When cells are delivered intracoronarily in a clinically relevant porcine model of chronic ischemic cardiomyopathy, the use of the stop-flow technique does not result in greater myocardial cell retention at 24 h compared with non-occlusive infusion. These results have practical implications for the design of cell therapy trials. Our observations suggest that the increased risk of complications secondary to coronary manipulation and occlusion is not warranted.
Collapse
Affiliation(s)
- Matthew C L Keith
- Institute of Molecular Cardiology, University of Louisville, 550 S Jackson Street, ACB Bldg, 3rd Floor, Louisville, KY, 40202, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Sun JC, Xu M, Lu JL, Bi YF, Mu YM, Zhao JJ, Liu C, Chen LL, Shi LX, Li Q, Yang T, Yan L, Wan Q, Wu SL, Liu Y, Wang GX, Luo ZJ, Tang XL, Chen G, Huo YN, Gao ZN, Su Q, Ye Z, Wang YM, Qin GJ, Deng HC, Yu XF, Shen FX, Chen L, Zhao LB, Wang TG, Lai SH, Li DH, Wang WQ, Ning G. Associations of depression with impaired glucose regulation, newly diagnosed diabetes and previously diagnosed diabetes in Chinese adults. Diabet Med 2015; 32:935-43. [PMID: 25439630 DOI: 10.1111/dme.12649] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/25/2014] [Indexed: 12/29/2022]
Abstract
AIM To examine the association between depression and impaired glucose regulation, newly diagnosed diabetes and previously diagnosed diabetes in middle-aged and elderly Chinese people, and whether depression was associated with different treatment regimens or durations of diabetes. METHODS A cross-sectional study was performed among 229,047 adults living in the community aged ≥ 40 years from 25 centres in China. The self-reported depression rating scale Patient Health Questionnaire 9 (PHQ-9) was used to diagnose probable and sub-threshold depression. Glucose metabolism status was determined according to World Health Organization 1999 diagnostic criteria. RESULTS The numbers of participants with normal glucose regulation, impaired glucose regulation, newly diagnosed diabetes and previously diagnosed diabetes were 120,458, 59,512, 24,826 and 24,251, respectively. The prevalence of sub-threshold depression in the total sample of participants was 4.8% (4.8%, 4.8%, 4.4% and 5.6% from normal glucose regulation to previously diagnosed diabetes, respectively), and the prevalence of probable depression was 1.1% (1.1%, 1.0%, 0.9% and 1.8% from normal glucose regulation to previously diagnosed diabetes, respectively). Compared with participants with normal glucose regulation, those with previously diagnosed diabetes had increased odds of probable depression [odds ratio (OR) = 1.61, 95% confidence interval (CI) 1.39-1.87] and sub-threshold depression (OR = 1.14, 95% CI 1.06-1.24), after adjustment for multiple confounding factors. Newly diagnosed diabetes or impaired glucose regulation was not associated with depression. Among those with previously diagnosed diabetes, insulin treatment was associated with greater odds of depression compared with no treatment or oral anti-diabetic medicine. CONCLUSION Previously diagnosed diabetes, but not newly diagnosed diabetes or impaired glucose regulation, was associated with a higher prevalence of depression. Patients receiving insulin were more likely to have depression than those not receiving treatment or being treated with oral anti-diabetic medicine.
Collapse
Affiliation(s)
- J C Sun
- Laboratory of Endocrine and Metabolic Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - M Xu
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - J L Lu
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Y F Bi
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Y M Mu
- People's Liberation Army General Hospital, Beijing, China
| | - J J Zhao
- Shandong Provincial Hospital, Jinan, China
| | - C Liu
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China
| | - L L Chen
- Wuhan Xiehe Hospital, Huazhong University of Science and Technology School of Medicine, Wuhan, China
| | - L X Shi
- Affiliated Hospital of Guiyang Medical College, Guiyang, China
| | - Q Li
- The Second Affilliated Hospital of Haerbin Medical University, Haerbin, China
| | - T Yang
- The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
| | - L Yan
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Q Wan
- The Affiliated Hospital of Luzhou Medical College, Luzhou, China
| | - S L Wu
- Xinjiang Kelamayi Peoples Hospital, Kelamayi, China
| | - Y Liu
- The First Hospital of Jilin University, Changchun, China
| | - G X Wang
- The First Hospital of Jilin University, Changchun, China
| | - Z J Luo
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - X L Tang
- The First Hospital of Lanzhou University, Lanzhou, China
| | - G Chen
- Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China
| | - Y N Huo
- Jiangxi Peoples Hospital, Nanchang, China
| | - Z N Gao
- Dalian Municipal Central Hospital, Dalian, China
| | - Q Su
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Z Ye
- Zhejiang Center for Disease Control and Prevention, Hangzhou, China
| | - Y M Wang
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - G J Qin
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - H C Deng
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - X F Yu
- Wuhan Tongji Hospital, Huazhong University of Science and Technology School of Medicine, Wuhan, China
| | - F X Shen
- The First Affiliated Hospital of Wenzhou Medical University, The First Provincial Wenzhou Hospital of Zhejiang, Wenzhou, China
| | - L Chen
- Qilu Hospital, University of Shandong School of Medicine, Jinan, China
| | - L B Zhao
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - T G Wang
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - S H Lai
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - D H Li
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, >TX, USA
| | - W Q Wang
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - G Ning
- Laboratory of Endocrine and Metabolic Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
42
|
Tang XL, Rokosh G, Sanganalmath SK, Tokita Y, Keith MCL, Shirk G, Stowers H, Hunt GN, Wu W, Dawn B, Bolli R. Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction. Circ Heart Fail 2015; 8:757-65. [PMID: 25995227 DOI: 10.1161/circheartfailure.115.002210] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2015] [Accepted: 05/15/2015] [Indexed: 02/07/2023]
Abstract
BACKGROUND Although c-kit(pos) cardiac stem cells (CSCs) preserve left ventricular (LV) function and structure after myocardial infarction, CSC doses have been chosen arbitrarily, and the dose-effect relationship is unknown. METHODS AND RESULTS Rats underwent a 90-minute coronary occlusion followed by 35 days of reperfusion. Vehicle or CSCs at 5 escalating doses (0.3×10(6), 0.75×10(6), 1.5×10(6), 3.0×10(6), and 6.0×10(6) cells/heart) were given intracoronarily 4 h after reperfusion. The lowest dose (0.3×10(6)) had no effect on LV function and morphology, whereas 0.75, 1.5, and 3.0×10(6) significantly improved regional and global LV function (echocardiography and hemodynamic studies). These 3 doses had similar effects on echocardiographic parameters (infarct wall thickening fraction, LV end-systolic and end-diastolic volumes, LV ejection fraction) and hemodynamic variables (LV end-diastolic pressure, LV dP/dtmax, preload adjusted maximal power, end-systolic elastance, preload recruitable stroke work) and produced similar reductions in apoptosis, scar size, infarct wall thinning, and LV expansion index and similar increases in viable myocardium in the risk region (morphometry). Infusion of 6.0×10(6) CSCs markedly increased postprocedural mortality. Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persistence of donor cells and formation of new myocytes were negligible with all doses. CONCLUSIONS Surprisingly, in this rat model of acute myocardial infarction, the dose-response relationship for intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75×10(6) is necessary for efficacy; above this threshold, a 4-fold increase in cell number does not produce greater improvement in LV function or structure. Further increases in cell dose are harmful.
Collapse
Affiliation(s)
- Xian-Liang Tang
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Gregg Rokosh
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Santosh K Sanganalmath
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Yukichi Tokita
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Matthew C L Keith
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Gregg Shirk
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Heather Stowers
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Gregory N Hunt
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Wenjian Wu
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Buddhadeb Dawn
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.)
| | - Roberto Bolli
- From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.).
| |
Collapse
|
43
|
Keith MCL, Tang XL, Tokita Y, Li QH, Ghafghazi S, Moore IV J, Hong KU, Elmore B, Amraotkar A, Ganzel BL, Grubb KJ, Flaherty MP, Hunt G, Vajravelu B, Wysoczynski M, Bolli R. Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs. PLoS One 2015; 10:e0124227. [PMID: 25905721 PMCID: PMC4408046 DOI: 10.1371/journal.pone.0124227] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 02/27/2015] [Indexed: 01/04/2023] Open
Abstract
Background There is mounting interest in using c-kit positive human cardiac stem cells (c-kitpos hCSCs) to repair infarcted myocardium in patients with ischemic cardiomyopathy. A recent phase I clinical trial (SCIPIO) has shown that intracoronary infusion of 1 million hCSCs is safe. Higher doses of CSCs may provide superior reparative ability; however, it is unknown if doses >1 million cells are safe. To address this issue, we examined the effects of 20 million hCSCs in pigs. Methods Right atrial appendage samples were obtained from patients undergoing cardiac surgery. The tissue was processed by an established protocol with eventual immunomagnetic sorting to obtain in vitro expanded hCSCs. A cumulative dose of 20 million cells was given intracoronarily to pigs without stop flow. Safety was assessed by measurement of serial biomarkers (cardiac: troponin I and CK-MB, renal: creatinine and BUN, and hepatic: AST, ALT, and alkaline phosphatase) and echocardiography pre- and post-infusion. hCSC retention 30 days after infusion was quantified by PCR for human genomic DNA. All personnel were blinded as to group assignment. Results Compared with vehicle-treated controls (n=5), pigs that received 20 million hCSCs (n=9) showed no significant change in cardiac function or end organ damage (assessed by organ specific biomarkers) that could be attributed to hCSCs (P>0.05 in all cases). No hCSCs could be detected in left ventricular samples 30 days after infusion. Conclusions Intracoronary infusion of 20 million c-kit positive hCSCs in pigs (equivalent to ~40 million hCSCs in humans) does not cause acute cardiac injury, impairment of cardiac function, or liver and renal injury. These results have immediate translational value and lay the groundwork for using doses of CSCs >1 million in future clinical trials. Further studies are needed to ascertain whether administration of >1 million hCSCs is associated with greater efficacy in patients with ischemic cardiomyopathy.
Collapse
Affiliation(s)
- Matthew C. L. Keith
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Xian-Liang Tang
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Yukichi Tokita
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Qian-hong Li
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Shahab Ghafghazi
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Joseph Moore IV
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Kyung U. Hong
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Brandon Elmore
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Alok Amraotkar
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Brian L. Ganzel
- Department of Cardiothoracic Surgery, University of Louisville, Louisville, Kentucky, United States of America
| | - Kendra J. Grubb
- Department of Cardiothoracic Surgery, University of Louisville, Louisville, Kentucky, United States of America
| | - Michael P. Flaherty
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Gregory Hunt
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Bathri Vajravelu
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Marcin Wysoczynski
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
| | - Roberto Bolli
- Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
- * E-mail:
| |
Collapse
|
44
|
Tang XL, Rokosh G, Sanganalmath SK, Shirk G, Stowers H, Hunt GN, Dawn B, Bolli R. DOSE-DEPENDENT EFFECTS OF INTRACORONARY CARDIAC STEM CELLS IN RATS WITH ACUTE MYOCARDIAL INFARCTION. J Am Coll Cardiol 2015. [DOI: 10.1016/s0735-1097(15)60961-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Jones SP, Tang XL, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC, Kong M, Li Q, Bhushan S, Zhu X, Du J, Nong Y, Stowers HL, Kondo K, Hunt GN, Goodchild TT, Orr A, Chang CC, Ockaili R, Salloum FN, Bolli R. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res 2014; 116:572-86. [PMID: 25499773 DOI: 10.1161/circresaha.116.305462] [Citation(s) in RCA: 146] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
RATIONALE Despite 4 decades of intense effort and substantial financial investment, the cardioprotection field has failed to deliver a single drug that effectively reduces myocardial infarct size in patients. A major reason is insufficient rigor and reproducibility in preclinical studies. OBJECTIVE To develop a multicenter, randomized, controlled, clinical trial-like infrastructure to conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies. METHODS AND RESULTS With support from the National Heart, Lung, and Blood Institute, we established the Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR), based on the principles of randomization, investigator blinding, a priori sample size determination and exclusion criteria, appropriate statistical analyses, and assessment of reproducibility. To validate CAESAR, we tested the ability of ischemic preconditioning to reduce infarct size in 3 species (at 2 sites/species): mice (n=22-25 per group), rabbits (n=11-12 per group), and pigs (n=13 per group). During this validation phase, (1) we established protocols that gave similar results between centers and confirmed that ischemic preconditioning significantly reduced infarct size in all species and (2) we successfully established a multicenter structure to support CAESAR's operations, including 2 surgical centers for each species, a Pathology Core (to assess infarct size), a Biomarker Core (to measure plasma cardiac troponin levels), and a Data Coordinating Center-all with the oversight of an external Protocol Review and Monitoring Committee. CONCLUSIONS CAESAR is operational, generates reproducible results, can detect cardioprotection, and provides a mechanism for assessing potential infarct-sparing therapies with a level of rigor analogous to multicenter, randomized, controlled clinical trials. This is a revolutionary new approach to cardioprotection. Importantly, we provide state-of-the-art, detailed protocols ("CAESAR protocols") for measuring infarct size in mice, rabbits, and pigs in a manner that is rigorous, accurate, and reproducible.
Collapse
Affiliation(s)
- Steven P Jones
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Xian-Liang Tang
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Yiru Guo
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Charles Steenbergen
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - David J Lefer
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Rakesh C Kukreja
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Maiying Kong
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Qianhong Li
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Shashi Bhushan
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Xiaoping Zhu
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Junjie Du
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Yibing Nong
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Heather L Stowers
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Kazuhisa Kondo
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Gregory N Hunt
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Traci T Goodchild
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Adam Orr
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Carlos C Chang
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Ramzi Ockaili
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Fadi N Salloum
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.)
| | - Roberto Bolli
- From the Cardiovascular Division, Department of Medicine, Institute of Molecular Cardiology, School of Medicine (S.P.J., X.-L.T., Y.G., Q.L., X.Z., J.D., Y.N., H.L.S., G.N.H., A.O., R.B.) and Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences (M.K.), University of Louisville, KY; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD (C.S.); Department of Pharmacology, Center for Cardiovascular Excellence, Louisiana State University Health Sciences Center, New Orleans (D.J.L., S.B., K.K., T.T.G., C.C.C.); and Department of Medicine-Cardiovascular, Medical College of Virginia, Richmond (R.C.K., R.O., F.N.S.).
| |
Collapse
|
46
|
Luo J, Obal D, Dimova N, Tang XL, Rokosh G. Cardiac myocyte-specific transgenic ecSOD targets mitochondria to protect against Ca(2+) induced permeability transition. Front Physiol 2013; 4:295. [PMID: 24194719 PMCID: PMC3810602 DOI: 10.3389/fphys.2013.00295] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 09/27/2013] [Indexed: 11/13/2022] Open
Abstract
ecSOD function has prototypically been associated with the extracellular space due to its secretion and localization to the extracellular matrix. A myocyte-specific ecSOD transgenic mouse has shown that it can also be localized to the myocyte intracellular compartment and is capable of attenuating Reactive oxygen species (ROS) formation and increasing NO bioavailability after ischemia reperfusion. Here, the subcellular localization of transgenic ecSOD was further defined by subcellular fractionation, immunofluorescent confocal microscopy, and Western analysis. Its impact on mitochondrial function was assessed by mitochondrial permeability transition (MPT). ecSOD was found to exist in cytosolic and nuclear fractions in addition to membrane. Colocalization of ecSOD with myocardial mitochondria was further demonstrated by confocal microscopy and subcellular fractionation of mitochondria and Western analysis. Isolated ventricular myocytes from cardiac-specific transgenic ecSOD mice were protected from hypoxia reoxygenation injury. Increased ecSOD colocalization to myocardial mitochondria in ecSOD Tg hearts limited MPT in response to Ca(2+) challenge. These results demonstrate that ecSOD is not restricted to the extracellular space and can alter MPT response to Ca(2+) suggesting mitochondrial localization of ecSOD can affect key mitochondrial functions such as MPT which are integral to cell survival.
Collapse
Affiliation(s)
- Jianzhu Luo
- Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville , Louisville, KY, USA
| | | | | | | | | |
Collapse
|
47
|
Tang XL, Griffith JF, Qin L, Hung VW, Kwok AW, Zhu TY, Kun EW, Leung PC, Li EK, Tam LS. SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus 2013; 22:1162-8. [PMID: 23884986 DOI: 10.1177/0961203313498802] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The objective of this report is to assess the effect of systemic lupus erythematosus (SLE) disease itself on deterioration of bone mineral density (BMD), microstructure and bone strength. METHOD Thirty age-matched SLE patients on long-term glucocorticoids (GC) (SLE/GC), 30 SLE patients without GC (SLE/non-GC) and 60 healthy controls were examined. Areal BMD (aBMD) was measured by dual-energy X-ray absorptiometry. Bone geometry, volumetric BMD (vBMD), and architectural parameters at the nondominant distal radius were assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT). Bone strength was estimated by HR-pQCT-based micro-finite element analysis. RESULTS Adjusted for menopausal status and adjusted calcium level, when compared with controls, SLE/non-GC patients had significantly lower aBMD at femoral neck and total hip, and diminished radial total vBMD, cortical area, vBMD and thickness, respectively, by 8.3%, 8%, 2.7% and 9.2%, as well as significant compromised bone strength (stiffness, failure load and apparent modulus) by 8.3%, 9.1% and 9.5%, respectively. Similar alterations were also found in SLE/GC patients when compared to controls. In the premenopausal subgroup analysis, when compared with controls, total hip aBMD and radial cortical area were significantly lower in SLE/non-GC patients, and cortical area and thickness were significantly deficit in SLE/GC patients. However, no significant difference in any bone variables was present between SLE/GC and SLE/non-GC patients in the entire cohort or in the premenopausal subgroup. CONCLUSION SLE disease per se contributes to the deterioration in bone density, cortical microstructure and bone strength. This might help to explain the considerably higher fracture risk seen in SLE patients.
Collapse
Affiliation(s)
- X L Tang
- 1Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong; Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong; Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong; Jockey Club Centre of Osteoporosis Care and Control; The Chinese University of Hong Kong, Hong Kong; and Department of Medicine & Geriatrics, Tai Po Hospital, Hong Kong
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bolli R, Tang XL, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, Jneid H, Rota M, Leri A, Kajstura J. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013; 128:122-31. [PMID: 23757309 DOI: 10.1161/circulationaha.112.001075] [Citation(s) in RCA: 173] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Relevant preclinical models are necessary for further mechanistic and translational studies of c-kit+ cardiac stem cells (CSCs). The present study was undertaken to determine whether intracoronary CSCs are beneficial in a porcine model of chronic ischemic cardiomyopathy. METHODS AND RESULTS Pigs underwent a 90-minute coronary occlusion followed by reperfusion. Three months later, autologous CSCs (n=11) or vehicle (n=10) were infused into the infarct-related artery. At this time, all indices of left ventricular (LV) function were similar in control and CSC-treated pigs, indicating that the damage inflicted by the infarct in the 2 groups was similar; 1 month later, however, CSC-treated pigs exhibited significantly greater LV ejection fraction (echocardiography) (51.7±2.0% versus 42.9±2.3%, P<0.01), systolic thickening fraction in the infarcted LV wall, and maximum LV dP/dt, as well as lower LV end-diastolic pressure. Confocal microscopy showed clusters of small α-sarcomeric actin-positive cells expressing Ki67 in the scar of treated pigs, consistent with cardiac regeneration. The origin of these cycling myocytes from the injected cells was confirmed in 4 pigs that received enhanced green fluorescent protein -labeled CSCs, which were positive for the cardiac markers troponin I, troponin T, myosin heavy chain, and connexin-43. Some engrafted CSCs also formed vascular structures and expressed α-smooth muscle actin. CONCLUSIONS Intracoronary infusion of autologous CSCs improves regional and global LV function and promotes cardiac and vascular regeneration in pigs with old myocardial infarction (scar). The results mimic those recently reported in humans (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy [SCIPIO] trial) and establish this porcine model of ischemic cardiomyopathy as a useful and clinically relevant model for studying CSCs.
Collapse
Affiliation(s)
- Roberto Bolli
- Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Tang XL, Qin L, Kwok AW, Zhu TY, Kun EW, Hung VW, Griffith JF, Leung PC, Li EK, Tam LS. Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. Osteoporos Int 2013; 24:1817-26. [PMID: 23104200 DOI: 10.1007/s00198-012-2177-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2012] [Accepted: 09/19/2012] [Indexed: 11/25/2022]
Abstract
UNLABELLED Compared to controls, HR-pQCT at distal radius of SLE patients on chronic glucocorticoid (SLE/GC) revealed reduced bone area, vBMD, deteriorated microarchitecture, and unevenly distributed stresses limited to cortical bone. Despite similar trabecular quality, whole bone strength decreased in patients. These alterations may partly explain high fracture rates in SLE/GC. INTRODUCTION To assess bone geometric, densitometric, microarchitectural, and biomechanical properties in patients with systemic lupus erythematosus (SLE) on long-term glucocorticoid (GC) (SLE/GC) as compared with healthy controls. METHODS A total of 180 female SLE patients and 180 healthy controls were in this cross-sectional study to assess areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry. High-resolution peripheral quantitative computed tomography (HR-pQCT) and microfinite element analysis (μFEA) was performed at distal radius. RESULTS In addition to significantly lower aBMD at femoral neck, total hip and lumbar spine, cortical area, average volumetric BMD (vBMD) and cortical vBMD also significantly reduced by 5.3, 5.7, to 1.9 % in SLE patients, respectively. Deteriorations of cortical microarchitecture were pronounced in patients, with 6.3 % reduction in cortical thickness and 13.6 % higher in cortical porosity. Local stresses were more unevenly distributed through cortical bone in patients. SLE/GC patients had decreased whole bone stiffness, estimated failure load, and apparent modulus. Parameters related to trabecular bone density and microarchitecture were comparable between patients and controls. CONCLUSION In SLE/GC patients, despite a reduction in bone area, vBMD and deteriorated microarchitecture and unevenly distributed stresses limited to the cortical compartment, whole bone strength decreased. HR-pQCT and μFEA were promising in elucidating the potential underlying pathophysiology of bone loss and propensity to fracture in SLE/GC and provide us additional information about alterations of bone quality which might better predict fracture risk beyond aBMD in SLE/GC.
Collapse
Affiliation(s)
- X L Tang
- Department of Medicine & Therapeutics, The Chinese University of Hong Kong, 9/F, Clinical Science Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T., Hong Kong
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ma ZC, Hong Q, Wang YG, Liang QD, Tan HL, Xiao CR, Tang XL, Shao S, Zhou SS, Gao Y. Ferulic acid induces heme oxygenase-1 via activation of ERK and Nrf2. Drug Discov Ther 2012; 5:299-305. [PMID: 22466441 DOI: 10.5582/ddt.2011.v5.6.299] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
This study investigated the effect of ferulic acid (FA) on the up-regulation of heme oxygenase-1 (HO-1) in lymphocytes and the molecular mechanisms involved. Lymphocytes were treated with FA (0.001-0.1 μM) for certain times. Cell viability, the activity and level of expression of HO-1, and signal pathways were analyzed. FA significantly upregulated HO-1 expression both at the level of mRNA and protein in lymphocytes. Moreover, FA induced NF-E2-related factor (Nrf2) nuclear translocation and transcriptional activity, which is upstream of FA induced HO-1 expression. In addition, lymphocytes treated with FA exhibited activation of extracellular regulated kinase (ERK) and treatments with U0126 (an ERK kinase inhibitor) attenuated the FA induced activation of Nrf2, resulting in a decrease in HO-1 expression. Zinc protoporphyrin (ZnPP, a HO-1 inhibitor) markedly suppressed cytoprotection from radiation-induced cell damage by FA. Results suggested that the ERK signaling pathway controlled the anti-oxidation of FA by regulating the expression of the antioxidant enzyme HO-1.
Collapse
Affiliation(s)
- Z C Ma
- Beijing Institute of Radiation Medicine, Beijing, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|